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A STUDY OF CLINICAL PROFILE OF PATIENTS WITH      
MYOCARDIAL INFARCTION 
 
ABSTRACT: 
BACKGROUND: 
Cardiovascular Diseases (CVD) is a leading cause of non communicable morbidity 
and mortality in India. By the year 2030 CVD is projected to be the leading cause 
of death worldwide. One of the most important advances in cardiovascular 
research was the identification of risk factors associated with cardiovascular 
diseases with subsequent treatments developed and rigorously tested to modify the 
risk factors with the goal of preventing CVD. Although 80% of global burden of 
cardiovascular diseases occurs in low and middle income countries, knowledge of 
importance of risk factors is largely derived from developed countries. The effect 
of factors on risk of coronary artery disease in most regions of the world including 
developing countries like India remains largely unknown. Various studies have 
been conducted to identify risk factors associated with Cardiovascular Diseases. 
 
 
AIM: 
To study the symptoms, clinical profile, risk factors, complications and outcome in 
predominantly rural Indian population. 
 
MATERIALS AND METHODS: 
 An observational cross sectional study involving 200 patients admitted with a 
diagnosis of ST Elevation Myocardial Infarction in Tirunelveli Medical College 
between August 2013 and August 2014. Data was collected based on Inclusion and 
Exclusion criteria. 
INCLUSION CRITERIA:  
All patients admitted to our hospital with a diagnosis of MI. The final diagnosis of 
MI will be based on the following criteria: 
1. Ischemic chest pain for atleast 30 minutes 
2. ECG evidence of myocardial injury: 
 0.1 mv or more ST segment elevation in 2 contiguous limb leads or 
Development of pathological Q waves 
3. An increase in serial CPK-MB or serial Troponin T or I 
EXCLUSION CRITERIA: 
Patients admitted with MI who refused to give consent for the study. Patients who 
are known cases of CKD, OLD MI, post angioplasty, post CABG patients. 
The outcome of the patients at the end of one week was studied using TIMI 
(Thrombolysis In Myocardial Infarction) Risk Score calculated at the time of 
admission. The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta, USA. 
 
RESULTS: 
Among the 200 patients, 91% were discharged alive and 9% expired. The most 
common cause of death was cardiogenic shock. Among the 18 patients who 
expired, 14 patients had a Thrombolysis in Myocardial Infarction (TIMI) risk score 
of  9 and above  and the remaining four had a TIMI score of  5 to 8. Mortality was 
not seen in those with a TIMI risk score of below five. The association was 
statistically significant ( p<0.0001). In a subgroup analysis, In Young MI           
(<45 years), 91.7% were smokers, 88.9% consumed alcohol,  around 50%  had  
positive family history; 47% were leading a sedentary life style and everyone 
100% had low HDL. The percentage of smoking and alcoholism were higher in 
young MI group compared to overall study group and all the patients in the young 
MI group were male. 
CONCLUSION: 
Cardiovascular Diseases affect mainly economically productive age group in our 
country and has become a major public health burden. Smoking, Alcoholism, 
Diabetes, Hypertension and Dyslipidemia remain the most important modifiable 
risk factors. Patients with a higher TIMI Risk Score have a greater mortality.  
KEYWORDS: Cardiovascular diseases, Myocardial Infarction, Thrombolysis In 
Myocardial Infarction. 
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 INTRODUCTION 
Cardiovascular Diseases is an important cause of morbidity and mortality in the 
developed as well as the developing world. By 2030, WHO predicts that 33%of the 
deaths occurring worldwide will be caused by Cardiovascular diseases. With the 
epidemiologic transition well and truly taking place humans have travelled a long 
way from the stage of pestilence and famine to the stage of obesity and inactivity. 
Due to these factors we face a host of challenges and the morbidity due to 
cardiovascular diseases is accelerating with each passing day. In India alone 
Cardiovascular diseases account for 25% of  the total deaths. 
        In our country the CVD risk factors among the rural as well as the urban poor 
and middle class are on the rise. The demon of cardiovascular diseases is very 
much at our door step. This is a frightening scenario considering that India is home 
to almost 17% of   the world‘s population. With a bulging population not to 
mention the bulging waistline of the populace the challenges that lie ahead of us 
are monumental to say the least. Like many other non-communicable diseases , 
cardiovascular diseases have  a long latency and have  numerous modifiable risk 
factors . 
 
[10] 
 
 One of the important advances in cardiovascular research has been with regard to 
the identification of risk factors associated with cardiovascular diseases. Based 
on these  risk factors treatment plans have been drawn and meticulously tested with 
the goal of altering the outcome.  
          The major chunk of the global burden of  these diseases is from the low and 
middle-income countries like India. But the data regarding the importance of risk 
factors has been derived mainly from developed countries. 
          In a multifaceted country like ours, with various ethnicities, cultural and 
food patterns and above all with varied political outlooks on the aspects of  health  
coupled with significant infrastructure limitations has effectively prevented us 
from having completely representative comprehensive surveys with regard to 
demography. The disease and death registration systems is in a state of shambles. 
This has been a big bane of our health care system and has prevented us from 
taking pre-emptive measures. With a health care system as frail as ours with 
numerous lacunae it becomes even more imperative to initiate cost-effective 
solutions. 
 
[11] 
 
Numerous   studies   have   been   conducted   to   highlight   the   importance  of  
risk   factors associated with Cardiovascular diseases. This study is based on risks 
seen in predominantly rural population in and around Tirunelveli. 
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AIMS OF THE STUDY 
 
To study: 
1. The type of  presentation(symptoms) 
 
2.  The type of  MI 
 
3. The relative incidence of risk factors 
 
4. The Thrombolysis in Myocardial Infarction(TIMI) score 
 
5. Outcome 
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REVIEW OF LITERATURE: 
CORONARY ARTERY ANATOMY:
[1]
 
LEFT MAIN CORONARY ARTERY:  
It arises from the superior portion of Left aortic sinus, just below the sino tubular 
ridge of aorta. The sino tubular ridge separates the Sinus of Valsalva  and the 
smooth tubular portion of aorta.
 
 
FIG.1 CORONARY ARTERIAL SUPPLY 
 
[16] 
 
LMCA has a variable length ranging from 10to 15 mm and an internal  
diameter that varies from 3 to 6mm. It runs behind Right Ventricular 
outflow tract and divides into Left Anterior Descending Artery (LAD) and Left 
Circumflex Artery. In a few cases, LMCA may be absent and there may be 
separateostia for LAD and LCX arteries. In some cases LMCA trifurcates 
into  LAD , LCX  and  Ramus  Intermedius. 
 
LEFT ANTERIOR DESCENDING ARTERY: 
 It arises from the Left main Coronary Artery. This artery runs in the anterior 
interventricular groove along with the  Great Cardiac vein towards the apex of the 
heart. It divides into septal and diagonal branches. Wide variation exists regarding 
the size and the number of septal perforators and diagonals. The Left Anterior 
Descending Artery supplies the anterior part of the septum via the septal 
perforators and the anterior, apical and the lateral walls of the left ventricle via the 
diagonal branches. 
Commonly implicated in the majority of deaths due to Acute coronary Syndromes, 
it is commonly called ―Widow makers‘ artery‖. 
[17] 
 
 
FIG. 2 TOTAL OCCLUSION OF LAD- ANGIOGRAPHY 
LEFT CIRCUMFLEX ARTERY: 
This artery originates from Left Main Coronary Artery and runs along posterior 
atrio ventricular groove toward inferior interventricular  groove. It gives off  large 
obtuse marginal branches. These Branches supply lateral free wall of left ventricle. 
In a few percentage of Individuals, Left Circumflex Artery gives off  Posterior 
[18] 
 
Descending  Artery (Left-Dominance). It also gives Left Atrial Circumflex 
branches that Supply posterior and lateral part of the left atrium. 
 
FIG.3 ANGIOGRAPHY- CORONARY ARTERIES 
RIGHT CORONARY ARTERY: 
This artery originates from right anterior aortic Sinus inferior to the origin of  
LMCA and runs along the posterior right atrioventricular groove. Its first branch is 
the conus artery,then it gives the Sinoatrial nodal artery in around 60% of the 
individuals. In the remaining the  sinoatrial nodal artery arises from the Left 
Circumflex Artery  in just under 40%  of the cases with a few cases blood supply 
[19] 
 
coming from both the arteries. The Acute Marginal Branches arise from the mid 
portion of the vessel and supplies the anterior wall of the right ventricle. The RCA 
then gives posterolateral branches and continues as the posterior descending artery 
which supplies the lower part of the interventricular septum. Right dominance is 
seen in 85% of the individuals; that is RCA gives rise to the Posterior Descending 
artery and atleast one posterolateral branch. In the remaining 15%, in one half,  
Left Circumflex artery gives rise to the PDA and the posterolateral branches. In the 
other half ,PDA arises from the Right Coronary artery and the posterolateral 
branches from the Left circumflex Artery(co-dominant or balanced circulation). 
The Dominant artery usually gives rise to the Atrioventricular nodal artery which 
supplies the AV node.  
CORONARY COLLATERAL CIRCULATION:  
   When a coronary vessel becomes totally occluded blood flow persists through 
collateral vessels. These channels develop when intracoronary pressure gradient 
occurs between source and recipient vessel. The extent and the function of 
coronary collaterals vary from patient to patient.  In some, collaterals are well 
developed so that they are able to maintain perfusion at rest and also at sub 
maximal cardiac workloads
[2]
. Improved survival and a lower risk of 
cardiovascular events have been shown in patients with elevated distal coronary 
perfusion pressure due to recruitment of collaterals
[3] 
. Repeated episodes of 
[20] 
 
coronary ischemia cause proliferation of coronary collaterals, a process called 
arteriogenesis
[4]
. When stenosis of the coronary vessel exceeds 70% the increase in 
endothelial shear stress in the pre-existing collateral vessels cause a Nitric Oxide 
dependent vasodilatation. 
 
FIG.4  COLLATERAL CIRCULATION 
But human randomized clinical trials to improve angiogenesis in mature coronary 
vessels has been highly disappointing
[5]
. But this may be because of the fact that 
improvements in functioning of  the  myocardium may be due to altered cell 
growth and repair  rather than  angiogenesis.
[6]
 When Nitric Oxide synthesis is 
deficient, collaterals constrict and this can relieved by nitroglycerin.
[7]
 This is 
similar to what occurs in the coronary resistance vessels. 
[21] 
 
 
CORONARY MICROCIRCULATION: 
Individual coronary resistance arteries are a longitudinally distributed network and 
the mechanisms controlling the resistance in these arteries is variable. 
[8]
 These 
vessels dilate in a co-ordinated  manner so that they are able  to meet the demands 
of  the distal vascular bed  . This is done by shear stress mediated control of the 
blood vessels or through myogenic control. 
Epicardial arteries with a diameter greater than 400 micron are mainly regulated by 
shear stress. The resistance vessels are divided into resistance arteries and 
arterioles. The arteries are regulated by shear stress and  myogenic response 
whereas the arterioles are mainly controlled by local metabolic factors and they 
regulate the perfusion of coronary capillary bed. Average myocardial capillary 
density is around 3500/mm.square. The capillary density is considerably higher in 
the sub endocardium than the epicardium. 
MYOGENIC CONTROL: 
This is a mechanism by which vessels dilate in response to decrease in pressure 
and constrict when the pressure increases. It is due to the tone of smooth muscle 
[9]
. 
It is believed to be due to the activation of the L type calcium channels. It occurs 
[22] 
 
mainly in arterioles<100 micron diameter and is an important mechanism in 
coronary auto regulation
[10]
 . 
Kuo and colleagues have shown flow-induced dilatation of coronary vessels 
[8,11]
. 
This is mediated by NO and hence endothelium dependent. Endothelium 
Dependent Hyperpolarising factor ,an arachidonic acid metabolite primarily 
regulates epicardial conductance vessels
[12] 
 
         FIG.5 CORONARY MICROCIRCULATION 
 The resistance vessels are controlled by Nitric oxide
[11]
.   EDHF may be 
upregulated during acquired disease states when Nitric oxide is deficient and serve 
as a compensatory mechanism assisting vasodilation
[13]
. 
[23] 
 
 
 
VASCULAR BIOLOGY OF ATHEROSCLEROSIS: 
THE NORMAL ARTERY: 
The Normal Artery has three layers an innermost layer of tunica intima, middle 
layer of tunica media and the outer layer of  tunica adventitia.  
 
FIG.6 LAYERS OF ARTERIAL VESSEL WALL 
[24] 
 
 
TUNICA INTIMA:  
The tunica intima is composed of  a single layer of endothelial cells which rests on 
a basal lamina. The  internal  elastic lamina separates tunica intima and tunica 
media. The endothelial cells arise from precursor cells called Endothelial 
Progenitor Cells. 
These cells help to repair areas of endothelial desquamation 
[14,15]
. Older 
individuals have lowered levels of endothelial progenitor cells and hence less 
ability to repair any damage that occurs in the tunica intima 
[16]
. New evidence has 
challenged the belief that Endothelial Progenitor cells populate murine 
atherosclerotic plaques 
[17]
.There is a variable expression of endothelial genes in 
different types of blood vessels. This is mainly regulated by the local 
environment
[18] 
TUNICA MEDIA:  
The middle layer tunica media is composed of numerous layers of  smooth  muscle 
layers embedded in an extracellular matrix . The extracellular matrix is rich in 
elastin. This gives the tensile strength to the arteries. The external elastic lamina 
separates tunica media and tunica adventitia. 
[25] 
 
 
TUNICA ADVENTITIA: 
This layer consists of loosely arranged collagen fibrils along with vasa vasorum 
and free nerve endings. The two most common types of cells seen are the 
fibroblasts and mast cells. Experimental evidence in animal models have shown 
that mast cells may well have an important in atheroma formation and also a role in 
pathogenesis of aneurysms
[19]
. 
ATHEROMA FORMATION: 
The first step is accumulation of lipoprotein particles in the intimal layer followed 
by their aggregation
[20]
.Oxidative stress, including products found in modified 
lipoproteins, results in the elaboration of  various  cytokines locally. The oxidative 
stress occurs in the form of oxidation, glycation, etc. The cytokines formed, 
increase expression of adhesion molecules for leukocytes that cause their 
attachment and chemoattractant molecules that direct their migration into the 
intima. The leukocytes thus move between endothelial cell junctions or sometimes 
penetrate through endothelial cells, a process called transcytosis. The leukocytes, 
on entering the artery wall in response to chemoattractant cytokines such as 
monocyte chemoattractant protein 1 (MCP-1) encounter stimuli such as 
macrophage colony-stimulating factor 
[21,22]
.These colony stimulating factors result 
[26] 
 
in increased expression of scavenger receptors. Scavenger receptors mediate the 
uptake of modified lipoprotein particles and promote the development of foam 
cells. T cells also tend to adhere to the endothelium and this effect is also mediated 
by leukocyte adhesion molecules.
 
 
FIG.7 THROMBUS FORMATION 
The commonly implicated leukocyte adhesion molecules are Vascular Cell 
Adhesion Molecule 1(V-CAM1),Inter cellular adhesion 
[27] 
 
Molecule 1(ICAM-1), E selectin, P selectin, etc.  Macrophage foam cells are a  
source of mediators, such as further cytokines and  effector molecules like 
hypochlorous acid, superoxide anion (O2
−
), and matrix  metalloproteinases. These 
influences result in the migration of smooth muscle cells from the tunica media to 
the tunica intima. There is considerable variation between the smooth muscle cells 
found in the normal tunica media and those found in the intima of an evolving 
atheroma 
[23,24]
. Emerging evidence has challenged the concept of migration of 
blood borne smooth muscle cells into the plaques 
[25]
.Further division of  smooth 
muscle cells occur coupled with elaboration of extracellular matrix. 
But an important point to note is that smooth muscle death also occurs hand in 
hand along with smooth muscle cell proliferation and migration. Interactions 
between the Fas ligand and the Fas expressed on the surface of smooth muscle 
cells coupled with the action of various pro inflammatory cytokines results in the 
death of  smooth muscle cells. Thus the smooth muscle accumulation in the 
atheromatous plaque can be said as a finely done balancing act between smooth 
muscle cell replication  and  cell death. The extracellular matrix makes up the 
major volume of the plaque rather than the cells. It is composed of mainly collagen 
(types 1 and 3), proteoglycans like biglycan, aggrecan, decorin and versican.  As 
the atherosclerotic plaques grow they develop their own blood supply. This 
angiogenesis is favoured by Vascular endothelial growth factor(VEGF),placental 
[28] 
 
growth factor (PIGF), certain forms of fibroblast growth factor and oncostatin M. 
This helps the plaque to overcome limitations in oxygen and nutrient supply and 
maintain its growth a mechanism similar to tumour  angiogenesis
[26]
.In later stages, 
calcification can occur  and fibrosis continues, sometimes accompanied by smooth 
muscle cell death (including programmed cell death or apoptosis), yielding a 
relatively acellular fibrous capsule surrounding a lipid-rich core that may also 
contain dying or dead cells. 
 
PATHOPHYSIOLOGY OF MYOCARDIAL ISCHEMIA: 
The normal function of the heart muscle is supported by high rates of myocardial 
blood flow, oxygen consumption, and combustion of fat and carbohydrates 
(glucose and lactate). Under normal aerobic conditions, cardiac energy is mainly 
derived from fatty acids, which contribute around 60 to 90 percent for the synthesis 
of adenosine triphosphate (ATP). The rest of the energy (10 to 40 percent) comes 
from oxidation of pyruvate, formed from glycolysis and lactate oxidation. Almost 
all of the ATP formed comes from oxidative phosphorylation in the mitochondria; 
only a small amount of ATP (<2 percent) is synthesized by glycolysis. 
Approximately two-thirds of the ATP used by the heart goes to contractile 
[29] 
 
shortening; the remaining one-third is used by sarcoplasmic reticulum Ca
2+
 
ATPase and other ion pumps. 
 
FIG. 8 PATHOPHYSIOLOGY OF MYOCARDIAL ISCHEMIA 
When a major artery is suddenly occluded , a change in the metabolism occurs 
from aerobic or mitochondrial phosphorylation to anerobic glycolysis. This change 
occurs within a matter of seconds. This results in increased production of lactate 
and a fall in ph. This fall in ph leads to a greater ATP requirement in order to 
maintain calcium homeostasis 
[27]
. Myocardial ischemia occurs due to an imbalance 
[30] 
 
between oxygen supply and demand. Biochemical abnormalities begin at the onset  
of ischemia, loss of myocardial contractility occurs within 60 seconds and the loss 
of viability occurs around 20 to 40 minutes following total coronary occlusion. 
Two zones of myocardial damage are seen: a central zone with no or very low flow 
and a zone of collateral vessels in a surrounding marginal zone. The survival of the 
marginal zone is dependent on two variables , one being the level of ischemia and 
the other being the duration of ischemia.  
The extent of coronary collateral flow is one of the principal determinants of 
infarct size. Patients with well developed collaterals have low risk of developing an 
acute MI on total occlusion of coronary artery 
[28]
. These collaterals seem to be 
well developed in younger individuals and also those who have experienced 
previous episodes of angina 
[29]
. 
For the clinical diagnosis of acute myocardial infarction, the World Health 
Organization requires that at least two of the following three criteria be present:  
(1) a history of chest pain or discomfort; 
(2) a rise and subsequent fall in serum cardiac enzymes; and 
(3) the development of electrocardiogram (ECG) abnormalities (new Q waves or 
ST-segment or T-wave changes) on serially obtained ECGs.
[30] 
[31] 
 
 Since the ECG lacks sufficient sensitivity and specificity to detect myocardial 
necrosis, the presence of myocardial injury is often dependent upon the release of 
cardiac-specific serum markers such as troponin T, troponin I, and CK-MB. It has 
been shown that infarct size generally correlates with the peak rise in serum CK-
MB level.
[31] 
 
 
FIG.9 CLINICAL OUTCOME OF ATHEROMATOUS PLAQUE 
[32] 
 
WAVEFRONT PHENOMENON: 
The area of myocardium that is necrosed, usually depends on the duration  of 
coronary artery occlusion. This was first proved by Reimer and Jennings in an 
experiment using canine coronary artery which was occluded for variable duration. 
After only 15 min of occlusion, no infarct occurred. At 40 min, the infarct was sub 
endocardial, involving only the papillary muscle, placing 28 percent of the 
myocardium at risk. At 3 h following coronary artery occlusion and reperfusion, 
the infarct was significantly smaller compared with non reperfused permanently 
occluded infarct (62 percent of area at risk). The infarct size was greatest in 
permanent occlusion, becoming transmural and involving 75 percent of the area at 
risk
[32]
 . In the dog model, it is impossible to achieve 100 percent infarction of area 
at risk because of species-related native collaterals. In humans, it has been shown 
that approximately 40 percent of patients with acute MI have a well-developed 
collateral circulation 
[29]
. 
GROSS PATHOLOGICAL CHANGES: 
The earliest change that usually occurs in the evolution of an acute MI is the pallor 
of  the myocardium; this change usually occurs after 12 hours or later after the 
onset of irreversible ischemia. The detection of infarction can be enhanced by the 
use of tetrazolium salt solutions. These solutions form a colored precipitate on 
[33] 
 
gross section of fresh heart tissue in the presence of dehydrogenase-mediated 
activity. The tetrazolium salts [nitrobluetetrazolium (NBT) and 2,3,5-
triphenyltetrazolium chloride (TTC)] are dyes that are sensitive to the presence of 
tissue dehydrogenase enzyme activity, which is depleted in the infarcted 
myocardium. It has been shown that myocardial infarct can be detected by NBT as 
early as 2 to 3 h in the dog and a little less in the pig because of poor collaterals. 
[33]
 
Red (TTC) or blue color (NBT) will form only in the normal noninfarcted 
myocardium, thus revealing the pale, unstained infarcted region. In humans, the 
necrotic myocardium can be detected within 2 to 3 h after infarct by immersion of 
the fresh heart slices in a solution of TTC or NBT. TTC staining demonstrated a 
diagnostic sensitivity of 77 percent and a specificity of 93 percent compared with 
routine histology, with predictive values of positive and negative test of 81 and 91 
percent, respectively. 
 Enhancement of pallor is seen 24 hours after the onset of ischemia. In this era of 
thrombolytic therapy, most in-hospital patients will have received tissue 
plasminogen activator, streptokinase, or IIb/IIIa inhibitors, which lyse the 
thrombus and restore blood flow into the area of infarction. Therefore, in a 
reperfused infarct, the infarcted region will appear red from trapping of the red 
cells and hemorrhage due to the rupture of the necrotic capillaries . 
[34] 
 
However, if there has been no reperfusion, the area of the infarct is better defined 
at 2 to 3 days, with a central area of yellow discoloration surrounded by a thin rim 
of highly vascularized hyperemia. At 5 to 7 days, the regions are much more 
distinct, with a central soft area and a depressed hyperemic border. At 1 to 2 weeks 
healing begins, with infiltration by macrophages as well as early fibroblasts at the 
margins. At the same time, the infarct begins to be more depressed, especially at 
the margins, where organization takes place, and there is a white border . The time 
taken for the infarct to completely heal may vary from as early as 4 to 6 weeks in 
small infarcts to as long as 2 to 3 months when the area of infarction is large. 
Healed infarcts are white from the scarring, and the ventricular wall may or may 
not be thinned (aneurysmal). In general, infarcts that are transmural and confluent 
are likely to result in thinning. But this is not the case with nonconfluent and sub 
endocardial infarcts which usually don‘t result in thinning. 
LIGHT MICROSCOPIC CHANGES: 
The earliest morphologic characteristic of MI that occurs is the hypereosinophilic 
myocyte.This change is usually seen between 12 to 24 h after onset of chest pain.  
The hypereosinophilia of the cytoplasm is best visualized by routine hematoxylin 
and eosin staining. The myocyte striations appear normal and some chromatin 
condensation may be seen in the nucleus. The area of infarction may show 
interstitial edema; however, this change is difficult to appreciate in human autopsy 
[35] 
 
hearts.This finding is better appreciated in animal models.The earliest 
characteristic  change, the appearance of ‗wavy fibers‘ is best seen in experimental 
animal models  and they are believed to be the the result of stretching of the 
ischemic noncontractile fibers by the adjoining viable contracting myocytes.
[34]
 
Wavy fiber change is, however, nonspecific and occurs in the absence of ischemia, 
especially in the right ventricle. Neutrophil infiltration is present by 24 h at the 
border areas. As the infarct progresses between 24 and 48 h, coagulation necrosis 
is established, with various degrees of nuclear pyknosis, early karyorrhexis, and 
karyolysis. The  myocyte striations are preserved and the sarcomeres elongate. The 
border areas show prominent neutrophil infiltration by 48 h. 
After 3 to 5 days, the central portion of the infarct shows loss of  myocyte  nuclei 
and striations; in smaller infarcts, neutrophils invade within the infarct and 
fragment, resulting in more severe karyorrhexis (nuclear dust). Loss of myocyte 
striations is best visualised by Mallory's trichrome stain. Another stain that has 
been used to detect early areas of infarction is hematoxylin–basic fuchsin–picric 
acid. But this technique is not very reliable for the early detection (6 to 8 hours) of 
infarction in humans and hence not commonly used.  
Immuno histochemical staining has also been used to study early changes of 
necrosis, but these tests which  also include antibodies directed against creatine 
[36] 
 
kinase, ceruloplasmin, myoglobin, C-reactive protein, complement complex (C5b-
9), fibronectin, and others—have also not been found to be useful. In the border 
areas of the infarct macrophage and fibroblast proliferation can be seen. By 1 
week, neutrophils decline and granulation tissue is established, with neocapillary 
invasion as well as lymphocytic and plasma cell infiltration. Although lymphocytes 
may be seen as early as 2 to 3 days, they are not prominent at any stage of infarct 
evolution. Eosinophils may be seen within the inflammatory infiltrate but are 
present in only 24 percent of infarcts. There is phagocytic removal of the necrotic 
myocytes by macrophages, and pigment is seen within macrophages. 
By the second week, fibroblasts become the most dominant cell type, but their 
presence can be seen as early as day 4 at the periphery of the infarct. Necrotic 
myocytes are continuously removed and the fibroblasts  actively produce collagen 
and angiogenesis tends to occur in the area of healing. The healing continues to 
occur. Depending on the  amount of cardiac myocytes necrosed, the healing may 
be complete as early as 4 weeks, or sometimes take 8 weeks or longer to complete . 
The central area of infarction may remain unhealed, showing mummified myocytes 
for extended periods, despite the fact that the infarct borders are completely healed. 
For this reason, it is important to evaluate the age of the infarct by examining the 
border with noninfarcted muscle. 
[37] 
 
The magnitude of repair and healing is dependent not only on infarct size but also 
on local and systemic factors. If there is good collateral blood flow locally, healing 
will be relatively rapid, especially at the lateral borders, where viable myocardium 
interdigitates with necrotic myocardium. There may be various levels of healing 
within an infarct, because of differences in blood flow in adjoining vascular beds 
caused by variable extents of coronary narrowing. The border areas may show 
hemorrhage and contraction-band necrosis, depending on regional variations in 
blood flow. 
 In humans, if reperfusion occurs within 4 to 6 h following the onset of chest pain 
or ECG changes; there is myocardial salvage and the infarct is likely to be 
subendocardial without transmural extension. There will be a nearly confluent area 
of hemorrhage within the infarcted myocardium, with extensive contraction-band 
necrosis. The extent of hemorrhage is dependent on the extent of reperfusion of the 
infarct as well as the extent of capillary necrosis. The larger the infarct and the 
longer the duration of the infarct, the greater the hemorrhage. The degree of 
hemorrhage may be variable and non uniform, as blood flow is dependent upon the 
residual area of coronary narrowing and the amount of  thrombolysis. Within a few 
hours of reperfusion, neutrophils are evident within the area of necrosis, but they 
are usually sparse . In contrast to nonreperfused infarcts, neutrophils do not show 
concentration at the margins. However, reperfused infarcts often demonstrate areas 
[38] 
 
of necrosis at the periphery, with interdigitation with noninfarcted myocardium. 
Macrophages begin to appear by day 2 to 3 and stromal cells show enlarged nuclei 
and nucleoli by days 3 and . Neutrophil debris, which may be concentrated at the 
border areas in cases of incomplete reperfusion, is seen by 3 to 5 days. By days 3 
to 5, fibroblasts appear, with an accelerated rate of healing as compared to 
nonreperfused infarcts. By 1 week, there is collagen deposition, with disappearance 
of neutrophils; there is also prominence of macrophages containing pigment 
derived from ingested myocytes. Angiogenesis is prominent and lymphocytes are 
often seen. Infarcts at 5 to 10 days are more cellular, and there is prominent 
myocytolysis (loss of myofibrils). As early as 2 to 3 weeks, subendocardial infarcts 
may be fully healed. Some 5 to 10 layers of subendocardial myocytes are spared 
without necrosis. However, myofibrillar loss, which is a result of ischemia not 
severe enough to cause cell death, is prominent in this subendocardial zone. Larger 
infarcts and those reperfused after 6 h take longer to heal. Infarcts reperfused after 
6 h show larger areas of hemorrhage as compared to occlusions with more 
immediate reperfusion. However, myocytes maintain their striations, become 
stretched and elongated, and—as they do not respond to calcium influx—do not 
show significant contraction-band necrosis. Despite the fact that reperfusion should 
occur within 6 h of occlusion for maximal myocyte salvage, there appears to be 
some benefit in opening an artery regardless of the duration of coronary occlusion. 
[39] 
 
 
The No-Reflow Phenomenon 
This  phenomenon was first described by Kloner and Jennings in 1974.They used  
an experimental canine model of myocardial infarction 
[35]
 and  demonstrated 
homogenous distribution of thioflavin S dye after 40 min of ischemia and 
reperfusion; however, after 90 min of ischemia, areas of no reflow were identified 
mainly in the subendocardial regions as zones not staining with thioflavin S. 
Electron microscopic examination revealed swollen endothelial protrusions and 
membrane-bound intraluminal bodies, which obstructed the capillary lumen and 
resulted in plugging of the capillaries by red cells, neutrophils, platelets, and fibrin 
thrombi. The areas not stained by thioflavin S were characterized by low regional 
myocardial blood flow.  
Myocardial dysfunction associated with reperfusion of the ischemic myocardium 
has been termed as reperfusion injury. 
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TABLE-1 PATHOLOGICAL CHANGES IN MI 
  PERMANENT OCCLUSION/NO 
REPERFUSION  
REPERFUSION FOLLOWING 
OCCLUSION  
Time of 
Occlusion 
Gross Histologic Gross Histologic 
12 h No 
change/pallor 
Wavy fibers Mottled, 
prominent 
hemorrhage 
CBN 
24–48 h Pallor—
yellow, soft 
Hypereosinophilic 
fibers, PMNs at borders 
Prominent 
hemorrhage 
Hypereosinophilic 
fibers + CBN + 
PMNs + 
hemorrhage 
throughout 
3–5 days Yellow center, 
hyperemic 
borders 
Large number of PMNs 
at border, coagulation 
necrosis, loss of nuclei 
Prominent 
hemorrhage 
Aggressive 
phagocytosis 
profuse fibroblast 
infiltration + 
collagen77[None] 
6–10 days Yellow, 
depressed 
central infarct, 
tan-red 
margins 
Mummified fibers in 
center, macrophage 
phagocytosis + 
granulation tissue at 
borders 
Depressed 
red-brown 
infarct with 
gray-white 
intermingled 
Aggressive healing 
with greater 
collagen 
10–14 
days 
Gray red 
borders, 
infiltrating 
central tan-
yellow infarct 
if large 
Marked granulation 
tissue, collagen 
deposition, 
subendocardialmyocyte 
sparing 
Gray-white 
intermingled 
with brown 
Aggressive healing 
with greater 
collagen 
2–8 weeks Gelatinous to 
gray-white 
scar, greater 
healing at 
border zone 
Collagen deposition with 
prominent large 
capillaries 
White 
intermingled 
with groups 
of myocytes 
with red 
myocardium 
Collagen 
intermingled with 
groups of myocy 
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This is assessed by contractile performance, lowering of  the arrhythmogenic 
threshold, conversion of reversible to irreversible myocyte injury, and micro vessel 
dysfunction. Recent studies have shown that the angiographic no-reflow 
phenomenon is a strong predictor of major cardiac events, such as congestive heart 
failure, malignant arrhythmias, and cardiac death after MI. 
GLOBAL BURDEN OF CARDIOVASCULAR DISEASES: 
Cardiovascular diseases is the number one cause of deaths in all the continents of 
the world the solitary exception being Africa. Even in sub Saharan Africa 
cardiovascular diseases will be the major cause of mortality in the coming decade. 
According to a study the major burden  of cardiovascular diseases in terms of 
mortality and disability occur in middle and low income countries 
[36]
. Among all 
cause of deaths occurring world cardiovascular diseases alone account for around 
30% of the deaths 
[37]
. The patterns of diseases in humans have undergone major 
changes as a result of changes in food patterns, economy and demography. This 
change in the pattern of diseases is called epidemiologic transition. There is a shift 
from diseases related to infections to those associated with lifestyle changes
[38]
. 
This transition has occurred very rapidly in the developing countries which are 
unable to cope with the increasing burden. 
[42] 
 
TABLE-2 EPIDEMIOLOGICAL TRANSITION 
The epidemiologic transition encompasses four stages pestilence and famine, 
receding pandemics, degenerative and man-made diseases and delayed 
degenerative diseases
[39]
.In addition to this a fifth stage of obesity and inactivity 
STAGE DESCRIPTION 
TYPICAL 
PROPORTION 
OF DEATHS 
CAUSED BY CVD 
(%) 
PREDOMINANT 
TYPES OF CVD 
Pestilence and 
famine 
Predominance of malnutrition and 
infectious diseases as causes of 
death; high rates of infant and child 
mortality; low mean life 
expectancy 
<10 
Rheumatic heart 
disease, 
cardiomyopathies 
caused by infection, 
malnutrition 
Receding 
pandemics 
Improvements in nutrition and 
public health leading to decrease in 
rates of deaths caused by 
malnutrition and infection; 
precipitous decline in infant and 
child mortality rates 
10-35 
Rheumatic valvular 
disease, hypertension, 
CHD, stroke 
Degenerative 
and man-made 
diseases 
Increased fat and caloric intake and 
decreased physical activity leading 
to emergence of hypertension and 
atherosclerosis; with increased life 
expectancy, mortality from 
chronic, noncommunicable 
diseases exceeds mortality from 
malnutrition and infectious 
diseases 
35-65 CHD, stroke 
Delayed 
degenerative 
diseases 
CVDs and cancer are major causes 
of morbidity, mortality; better 
treatment and prevention efforts 
help avoid deaths in those with 
disease, delay primary events; age-
adjusted CVD mortality declines; 
CVD affecting older and older 
individuals 
40-50 
CHD, stroke, 
congestive heart 
failure 
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has also been described
[40]
.Here obesity, diabetes and lipid abnormalities are 
increasing in children.20% of Chinese people are overweight or obese 
[41]
 
The dynamics of  health transition are very different in the developing countries 
compared to the developed countries.  Compression of the time course of the 
cardiovascular epidemic along with inadequate public health infrastructure coupled 
with low levels of education and awareness about the disease, co-existing burden 
of communicable diseases are all major obstacles that prevent us from taking 
effective measures. 
    In India alone around 32 million people are believed to suffering from 
cardiovascular diseases 
[42]
.  Approximately 2.03 million deaths have been believed 
to have occurred due to cardiovascular diseases by 2010. In the 30 year period 
from 1990 to 2020, 111% increase in deaths due to cardiovascular diseases is 
expected
[42]
. Some studies indicate women are more likely to have cardiovascular 
diseases than men in India
[43]
. More than half of the Cardiovascular deaths in India 
occurred in people less than 70 years.  
A study conducted in south India in rural Andhra Pradesh has shown that 
prevalence may well be higher in rural areas
[44]
. Developing countries are affected 
a decade or two earlier than developed countries, often resulting in loss of a sole 
[44] 
 
bread- winnerof  the  family imposing a significant burden on the family as well as 
the community. 
RISK FACTORS: 
SMOKING: 
Smoking is the single most important risk factor for coronary artery disease. 
Cigarette consumption is the most important cause of preventable death in the 
world 
[45]
.  The use of tobacco is rising among women, adolescents and young 
adults
[46] 
. Around 930,000 adult deaths have been estimated to have occurred in 
India due to smoking related causes 
[47]
. Smoking causes acceleration of 
atherosclerosis, impairs vasodilatory capacity of coronary arteries, increases levels 
of stress hormones, increases bronchial secretions, impairs mucociliary clearance 
and aggravates associated pulmonary dysfunction. Passive smoking is equally 
hazardous. Smoking also causes : 
1.increased levels of oxidized LDL 
2.lowers levels of cardio protective HDL 
3.nicotine and carbon monoxide in smoke produce endothelial damage 
4.increases vascular reactivity  
5.lowers threshold for myocardial ischemia; increases coronary vasospasm 
[45] 
 
6.increases fibrinogen levels and platelet aggregability. 
 Cessation of cigarette consumption remains the single most important intervention 
in preventive cardiology. A study demonstrated, smoking cessation reduced 
cardiovascular mortality by 36% as compared with mortality in subjects who 
continued smoking, an effect that did not vary by age, sex, or country of origin
[48]
. 
Reductions in smoking from any mechanism improve health outcomes, 
especiallywhen coupled along with lifestyle changes, including exercise and 
dietary control. Trials of nicotine replacement therapy using transdermal nicotine 
or nicotine chewing gum increase abstention rates after cessation. Such 
pharmacologic programs, as well as physician-guided counseling, are cost-
effective and should be provided as standard prevention services. Low-yield 
cigarettes do not appear to reduce the risks of myocardial infarction. Although the 
elevated cardiovascular risks associated with smoking decrease significantly after 
cessation, the risks of cancer of the lungs, pancreas, and stomach persist for more 
than a decade, as do the risks of developing chronic obstructive pulmonary disease. 
Smoking cessation has clear benefit, but smoking reduction alone appears to have 
only a marginal effect. Patients often do not understand the importance of smoking 
cessation. This is common especially in the developing world where low levels of 
literacy and awareness hamper smoking cessation programs. 
[46] 
 
 
Studies of social networking indicate that smoking cessation by a spouse decreases 
a person's chance of smoking by 67%.Smoking cessation by a brother or sister, 
friend, or neighbour, people who work in the same environment decreases a 
person's chance of smoking by 25% to 36%. Smoking cessation programs that have 
provided direct financial benefits to those who have stopped smoking have found 
to be effective. But the most important component of any effective smoking 
reduction strategy is health education to the community and physician based 
primary prevention program
[49]
. 
HYPERTENSION: 
The prevalence of hypertension is steadily increasing in the Indian population. The 
total number of adults with hypertension in the world  is anticipated to exceed 1.5 
billion
[50]
.Worldwide, hypertension causes 7.6 million premature deaths annually, 
with 80% of this burden occurring in low- and middle-income countries
[51]
.  
Isolated systolic hypertension, in particular, has at least as much importance as 
diastolic blood pressure for the outcomes of total cardiovascular mortality and 
stroke. There is strong evidence favouring the treatment of  systolic hypertension 
even in the older adults .Pulse pressure, generally reflecting vascular wall stiffness, 
also predicts first and recurrent myocardial infarction. Pulse pressure is defined as 
[47] 
 
the difference between systolic and diastolic blood pressures. Pulse pressure 
appears to predict cardiovascular events independently, particularly heart failure. 
Home-based monitoring of blood pressure  is a better indicator for vascular events 
than office-based evaluation 
[52]
.Nocturnal hypertension diagnosed by continuous 
ambulatory blood pressure monitoring is associated with an increased risk of 
congestive cardiac failure .Self-measurement helped in the detection of those with 
white coat hypertension but did not  improve overall management.It also did not  
alter the objective measures of compliance, like left ventricular mass. Blood 
pressure reductions as miniscule as 4 to 5 mm Hg result in large and clinically 
significant reductions in risk for stroke, vascular mortality, congestive heart failure, 
and total CHD in people of all age groups irrespective of race such including those 
with diabetes and peripheral arterial disease. 
     Though non pharmacological measures like diet and life-style management 
have an important role in control of hypertension when used alone the results have 
been disappointing. But Diet and lifestyle changes have an important role in the 
prevention of hypertension and they can reduce the burden of high blood pressure 
in the community. Multiple drug regimens involving anti hypertensives at low 
doses capable of reducing systolic blood pressure  by 20mm Hg and diastolic blood 
pressure by 11mm Hg have reduced the risk of stroke and CHD by 63% and 46% 
respectively
[53]
. The ACCORD trial(ACTION TO CONTROL 
[48] 
 
CARDIOVASCULAR RISK IN DIABETES) showed that in diabetic patients 
aiming for systolic BP less than 120mm Hg as compared to 140mm Hg did not 
reduce the rate of cardiovascular events
[54]
. In order to maintain clinical benefits 
blood pressure control must be maintained life-long. Another important aspect is 
that hypertension co exists with glucose intolerance, insulin resistance, 
hyperinsulinemia ,obesity, left ventricular hypertrophy and renal failure making its 
treatment complicated. 
       Hypertension increases risk of coronary events by 
1.impairing function of the endothelium 
2.increased endothelial permeability to lipoproteins 
3.increased oxidative stress 
4.increased adherence to leukocytes 
5.acute plaque rupture due to haemodynamic stress 
6.increasing oxygen demand of myocardium 
7.decreasing myocardial compliance and impaired myocardial relaxation 
8.increasing myocardial wall stress. 
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DYSLIPIDEMIA: 
Cross-sectional population studies have consistently revealed a relationship 
between serum cholesterol levels and CHD death. The validity of such studies are 
however limited by the presence of multiple confounding factors. The emergence 
of data from prospective cohort studies, such as that begun in Framingham in the 
1950s, bolstered the relationship between cholesterol and CHD. This study, as well 
as others performed with different populations around the world, established the 
concept of cholesterol more firmly as a culprit in CHD.  
Although based on experimental and clinical observation, doubts persisted 
regarding the role of cholesterol in atherosclerosis until very recently. Through the 
beginning of the 1990s, controversy enveloped the role of cholesterol-lowering 
therapy in CHD risk reduction. Despite evidence that high cholesterol levels 
correlated with coronary death, the proposition that cholesterol-lowering therapy 
could reduce CHD morbidity remained unproven. Critics pointed to the J-shaped 
curve, which apparently described the relationship of serum cholesterol to 
mortality. Advocates of the cholesterol hypothesis countered that the heightened 
risk for all-cause death in individuals with low levels of cholesterol might reflect 
co morbidities such as cancer, inanition, or liver disease. The goal of reducing 
CHD mortality by drug therapy eluded convincing proof for decades. Some 
[50] 
 
cholesterol-lowering medications appeared to cause an increase in the incidence of 
some events, including non coronary death. In the pioneering coronary drug 
project, estrogen treatment led to excess mortality in the cohort of men studied. 
The World Health Organization study of clofibrate showed excess non coronary 
death. Dietary interventions to lower cholesterol often proved ineffective and, 
together, such results seemed to challenge the validity of cholesterol as a 
therapeutic target. 
Conclusive evidence regarding the cholesterol hypothesis awaited clinical trials of 
cholesterol lowering using the hydroxyl methyl glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors (statins), agents that lowered LDL cholesterol much more 
efficiently than previously available drugs. Unassailable clinical trial evidence now 
shows that lowering LDL cholesterol levels reduces coronary events in broad 
segments of the population. The ensemble of large clinical trials of statins has 
substantiated a decrease in total mortality in almost all major study populations. As 
a group, placebo-controlled trials of statins lowered LDL cholesterol levels by 20% 
to 60% and reduced coronary events by up to one third over a 5-year period, with 
no evidence of an increase in nonvascular mortality. 
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The Heart Protection Study showed that statins can reduce stroke and coronary 
events in those with preexisting vascular disease. Several head to head trials 
comparing different statin regimens have shown that even more aggressive LDL 
reduction is associated with greater clinical improvements . 
The case for LDL cholesterol as a CHD risk factor thus meets most of the criteria 
established by Robert Koch in the 19th century to establish a causative agent in a 
disease. High cholesterol levels consistently predict risk of future cardiovascular 
events in human populations. Animal studies in multiple species have shown a 
causal relationship between hypercholesterolemia and atherosclerosis. Knowledge 
of the LDL receptor pathway plus emerging understanding of the vascular biology 
of atherosclerosis provides biologic plausibility for the involvement of LDL in 
atherogenesis. The human mutations in the LDL receptor produce 
hypercholesterolemia on a monogenic basis that causes accelerated atherosclerosis 
as early as the first decade of life in individuals with homozygous familial 
hypercholesterolemia. Finally, interventions in large clinical trials to lower LDL 
cholesterol levels by various approaches (e.g., bile acid–binding resins, intestinal 
bypass surgery, statins) have shown a reduction in cardiovascular events. Thus, 
LDL cholesterol fulfills the criteria of modified Koch's postulates as one causative 
agent in atherosclerosis. 
[52] 
 
Several independent lines of evidence have suggested that what is regarded as 
―normal‖ cholesterol levels in Western society exceed levels that good health 
requires.
[55]
 In particular, certain rural agrarian societies with very low rates of 
atherothrombosis have total cholesterol levels well below those accepted as normal 
in Western societies. Another line of evidence derives from phylogeny. 
Contemporary humans have much higher total cholesterol levels than those of 
many other species of higher organisms that thrive nonetheless. Clinical trials have 
shown that LDL cholesterol levels as low as 50 mg/dL provide optimal outcomes, 
even in primary prevention. 
Cholesterol levels measured early in life influence long-term cardiovascular risk. 
Substantial evidence suggests that the burden of risk for cardiovascular disease 
begins in young adulthood. Autopsy studies from the Korean and Vietnam 
conflicts, and recent explorations of coronary anatomy by intravascular 
ultrasonography, indicate that atherosclerosis affects adolescents in our society. In 
very high-risk children, clinical trial evidence has demonstrated the efficacy of 
statin therapy for lipid-lowering in familial hypercholesterolemia. Statin trials have 
now demonstrated convincing benefits on hard clinical endpoints, even among 
those without established cardiovascular disease. Not all patient subgroups, 
however, have shown such clear benefits with statin therapy. In those with severe 
congestive heart failure or on hemodialysis, recent trials have not found lowered 
[53] 
 
event rates in statin-treated patients, suggesting that the use of these agents late in 
the disease process may yield less benefit. 
As is the case with LDL cholesterol, abundant prospective cohort studies have 
demonstrated a strong inverse relationship between high-density lipoprotein (HDL) 
cholesterol and vascular risk. In general, each increase of HDL cholesterol by 
1 mg/dl is associated with a 2% to 3% decrease in risk of total cardiovascular 
disease. Patients with angiographically proven coronary artery disease more often 
have low levels of HDL than high levels of LDL, as defined by current criteria. 
The process of reverse cholesterol transport may explain in part the apparent 
protective role of HDL against coronary death. According to this concept, HDL 
could ferry cholesterol from the vessel wall, augmenting peripheral catabolism of 
cholesterol . HDL can also carry antioxidant enzymes that may reduce the levels of 
oxidized phospholipids in atheromatous lesions, which could enhance 
atherogenesis. Furthermore, overexpressing the apolipoprotein A-I gene in 
transgenic mice and infusing complexes of apolipoprotein A-I and phospholipids 
into hyperlipidemic rabbits not only increases HDL cholesterol levels (HDL-C) but 
also decreases atherosclerotic development. Evidence is also accruing of anti-
inflammatory properties for HDL-C. 
[54] 
 
In contrast to LDL, however, we currently lack evidence that increasing HDL-C 
levels reduces risk. The Investigation of Lipid Level Management to Understand 
Its Impact in Atherosclerotic Events (ILLUMINATE) trial, in which the 
cholesteryl ester transfer protein inhibitor torcetrapib was given to patients at high 
vascular risk, showed an unanticipated increase in all-cause mortality,
[56]
 findings 
that have led to considerable controversy as to whether HDL-C remains a viable 
therapeutic target. 
            Nonetheless, the consistency of the observational data, both cross-sectional 
and prospective, strongly supports the HDL level as a negative risk factor, as 
incorporated in the Adult Treatment Panel (ATP-III) guidelines, and supports the 
continued careful evaluation of agents that can directly increase HDL levels. This 
recognition by the ATP-III—that a biomarker can be useful without fulfilling 
Koch's postulates—has importance for clinical practice and has implications for 
several other emerging risk factors (see later). Optimism that HDL-C remains in 
the causal pathway for atherosclerotic events also comes from recent genetic 
studies evaluating the relationships of polymorphisms in HDL-related loci as 
predictors of incident vascular events. 
 
Several investigators have suggested that the measurement of 
apolipoproteins A-I and B100 would predict cardiovascular risk better  
[55] 
 
than HDL and LDL cholesterol in clinical practice. Two recent 
prospective cohort studies have shown this to be the case for men
[57]
 and 
women.
[58]
 However, both of these studies also found that non-HDL 
cholesterol (defined as total cholesterol minus HDL cholesterol) 
provided clinical risk information at least as strong as that of 
apolipoprotein B100; this was an unsurprising observation, because non–
HDL-C correlates very closely with apolipoprotein B100 levels. 
Furthermore, these studies found that the total cholesterol–to–HDL-C 
ratio remained a very strong predictor of risk, superior even to the ratio 
of apolipoprotein B100 to apolipoprotein A-I. Thus, despite evidence 
favoring apolipoproteins A-I and B100 in univariate analyses as 
replacements for HDL and LDL cholesterol, there remain little clinical 
data that use of these measures improves overall risk prediction 
compared with standard lipid testing. 
 
Beyond standard chemical measures of total, LDL, and HDL cholesterol, 
which appropriately form the basis of current lipid screening and 
reduction guidelines, the amount of cholesterol carried by different 
classes of lipoprotein particles may influence function and vary widely 
among individuals. Therefore, measures of core lipid composition and 
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lipoprotein particle size have been hypothesized to provide better 
measures for risk prediction. Several lines of evidence have indicated 
that small LDL particles may be more atherogenic than large particles 
and contribute particularly to the dyslipidemia of diabetes. Currently, a 
number of technologies are available for the evaluation of LDL 
subclasses and particle size. Studies using density gradient 
ultracentrifugation and gradient gel electrophoresis have generally found 
that lipoprotein subclass identifies individuals at higher risk for coronary 
disease and have successfully shown a preferential benefit of lipid-
lowering therapy for patients with small, dense LDL particles compared 
with large LDL particles. LDL particle concentration, as measured by 
nuclear magnetic resonance (NMR) studies, correlates well with 
coronary arterial lumen diameter after statin therapy and may offer 
predictive value for future vascular events. In both the Women's Health 
Study and the Multi-Ethnic Study of Atherosclerosis, LDL particle 
concentration measured by NMR predicted incident vascular events 
better than standard chemical measurement of LDL cholesterol.
[41,42]
 
However, in these studies, lipoprotein profiles evaluated by NMR were 
not superior to those of other standard measures, such as the total 
cholesterol–to-HDL-C ratio or non–HDL-C. Thus, although intriguing 
[57] 
 
pathophysiologic information regarding lipid reduction with statins and 
gemfibrozil has come from NMR studies, as well as density gradient 
studies, it remains unclear whether these novel methods of lipid 
evaluation add importantly to standard lipid screening in routine practice 
or should remain specialized tools for research and lipid clinics. 
 
Triglyceride-Rich Lipoproteins and Cardiovascular Risk  
In contrast to compelling evidence favoring a causal role for LDL-C in 
atherogenesis, the role of triglycerides remains controversial. Part of this 
controversy reflects the inverse correlation of triglyceride levels with HDL-C. 
Adjustment for HDL-C attenuates the relationship between triglycerides and 
cardiovascular disease. A recent meta-analysis has suggested that the adjusted risk 
ratio for coronary disease among those in the top third of triglyceride levels, 
compared with the bottom third, decreases from approximately 2.0 to 1.5 after 
accounting for HDL-C.
[45]
 A second controversy reflects the continued 
recommendation in guidelines that triglycerides be measured in the fasting state, 
whereas much of the prognostic value of plasma triglyceride levels depends on 
postprandial levels. Two major cohort studies have recently reported that 
nonfasting triglycerides predict vascular events, independent of traditional risk 
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factors, but that fasting triglyceride levels show little independent 
relationship.
[46,47]
On this basis, prediction of vascular risk may need to be based on 
an oral triglyceride tolerance test, analogous to a glucose tolerance test used to 
diagnose diabetes.
[48]
Nonfasting triglycerides have also recently been found to 
predict incident stroke, again in contrast to fasting levels.
[49]
 
For these reasons, among others, current guidelines do not establish a target value 
of triglycerides. However, in view of the tight link of triglyceride levels with 
known risk factors for atherosclerosis (e.g., low HDL-C level, uncontrolled 
diabetes, hypothyroidism), the finding of marked and persistently elevated 
triglyceride levels should enter into overall risk assessment for an individual and 
stimulate consideration of the reason for triglyceride level elevation, including 
careful exclusion of secondary causes . A cautious approach to triglyceride 
reduction seems prudent, because randomized trials using fenofibrate in diabetic 
patients have not shown significant reductions in risk when added to statin therapy. 
DIABETES: 
The demon of diabetes is taking a meteoric toll on the India population. India and 
China house a very large number of world‘s diabetic population. China is home to 
around 90 million diabetics and India the number hovers around 61 million 
according to a study by International Diabetes Federation (IDF) in 2011.Both 
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countries are in a neck and neck race to earn the dubious distinction of  ‗Diabetic 
Capital‘ of the world. 
     Indians in particular are affected by diabetes at a younger age, they tend to be 
leaner, exibhit higher degrees of insulin resistance and have abdominal obesity. 
According to a study, if a patient develops diabetes, the disease conferred a risk 
equivalent to 15 years aging 
[59]
. This is much higher than that conferred by 
smoking. Diabetes causes acceleration of atherosclerosis in the major arteries in 
addition to increasing the atherosclerotic burden in the microvasular tone. Even 
before diabetes becomes evident clinically, cardiovascular risk seems to 
increase
[54]
. Insulin resistance commonly a twin of obesity, by itself increases the 
rate of atherosclerosis. It also increases the risk of  heart failure. Diabetes leads to 
widespread endothelial dysfunction, increased oxidative stress, impaired 
fibrinolysis coupled with increased platelet aggregability. This is done through 
various mechanisms. Alterations in the coagulation pathway due to increased 
levels of  tissue thromboplastin, factor vii, increased amounts of von Willebrand 
factor coupled with decreased levels of antithrombin iii, proteinC, proteinS, etc 
leads to a prothrombotic state.The accumulation of advanced glycation end 
products also contributes to inflammation.  
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TABLE -3 MECHANISMS OF DIABETIC VASCULAR DISEASE 
Endothelium 
    ↑ NF-κβ activation 
    ↓ Nitric oxide production 
    ↓ Prostacyclin bioavailability 
    ↑ Endothelin 1 activity 
    ↑ Angiotensin II activity 
    ↑ Cyclooxygenase 2 activity 
    ↑ Thromboxane A2 activity 
    ↑ Reactive oxygen species 
    ↑ Lipid peroxidation products 
   
 ↓ Endothelium-dependent 
relaxation 
    ↑ RAGE expression 
 
Vascular smooth muscle cells and 
vascular matrix 
   
 ↑ Proliferation and migration into 
intima 
    ↑ Increased matrix degradation 
    Altered matrix components 
 
Inflammation 
    ↑ IL-1β, IL-6, CD36, MCP-1 
    ↑ ICAMs, VCAMs, and selectins 
    ↑ Activity of protein kinase C 
   
 ↑ AGEs and AGE/RAGE 
interactions 
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The insulin resistance syndrome or metabolic syndrome comprises  abdominal 
obesity as seen by increased waist circumference ,elevated triglycerides, low HDL, 
elevated blood pressure, increased blood sugar values. Its definition and diagnostic 
criteria have varied depending on study groups and national guidelines and is 
mired in ambiguities. But what is not in doubt is that the metabolic syndrome leads 
to increased cardiovascular and all cause mortality
[60]
. Though central obesity 
,which is calculated by measuring  waist circumference,is an integral component  
of metabolic syndrome, there are not many studies which have measured visceral 
fat deposition. Visceral fat deposition is believed to be the main driver of 
dysmetabolism
[61]
. Nowadays the definition of metabolic syndrome includes a pro 
inflammatory state as evidenced by elevated hs CRP levels in these  patients
[62]
.  
EXERCISE: 
Regular exercise reduces the risk of cardiovascular diseases. Earlier it was believed 
for exercise to be beneficial, it must be vigorous. But recent evidence indicates that 
exercising in moderation confers significant cardiovascular benefits. Exercise 
improves insulin sensitivity, lowers LDL and total cholesterol levels, improves 
HDL levels and lowers triglyceride levels. These benefits tend to occur even in the 
absence of clinically significant weight loss. 
[62] 
 
Studies have shown that if children increase the time spent in physical activity  by 
more than one hour daily occurrence of cardiovascular risk factors at an early age 
can be prevented
[63]
.Exercise further improves insulin sensitivity and glycemic 
control, with major benefits for diabetic patients, including reductions in glycated 
hemoglobin and reduced requirements for therapy. Various studies have shown 
that even moderate intensity exercise has significantly reduced the incidence of 
diabetes.  Regular exercise lowers CRP levels, improves coronary endothelial 
function, and appears to benefit hemostatic variables, including tissue-type 
plasminogen activator, fibrinogen, von Willebrand factor, fibrin, D-dimer and 
plasma viscosity. 
Chronic exercise training appears to have a considerably favorable influence on 
endothelial function in the peripheral arteries and the coronary arteries. This effect 
is due to the increased production of vasodilating nitric oxide which leads to a 
decrease in oxidative stress. Regular exercise also tends to increase levels of 
endothelial progenitor cells.  Such improvements have been linked to a reduction 
in adverse cardiovascular events. Finally, exercise training appears to modulate the 
balance between sympathetic and parasympathetic tone favorably, an effect 
associated with improvements in survival. 
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NUTRITION: 
‗A man is what he eats‘. This old saying assumes significance in the current era 
because of the unhealthy food habits we tend to follow.  Increased consumption  of 
dietary salt and foods rich in trans-fatty acids coupled with lower intake of omega-
3 fatty acids, fruits, and vegetables, are some of the major modifiable causes of 
both total deaths and deaths from cardiovascular disease (CVD). In many countries 
including India, the bulging waistline of the population and the associated increase 
in   obesity, DM, and CVD are primarily due to rapid social and environmental 
changes transmitted mainly by dietary changes and other lifestyle changes. 
Knowledge of how diet affects CVD has rapidly progressed in recent years. 
Earlier, the association between food and cardiovascular diseases was based 
primarily on data from ecologic studies and short-term experiments. But now 
evidence is being derived from well conducted randomized control trials and 
prospective cohort studies of disease endpoints (e.g., myocardial infarction [MI], 
CHD death) that provide direct evidence for total causal effects in addition to well-
conducted trials of multiple risk markers and pathways . Conclusions are most 
robust when studies across these different designs provide concordant findings, 
with supporting evidence from in vitro and animal work, retrospective studies, and 
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ecologic studies. Dietary factors exert acute and chronic effects on a complex set 
of established and novel risk factors, mechanistic pathways, and disease conditions. 
Total carbohydrate quantity consumed does not associate strongly with CHD risk, 
but the types and quantity of carbohydrate consumed are important determinants of 
health effects. Dietary fiber is comprised of nondigestible polysaccharides, 
resistant starch and oligosaccharides, and lignins in plants. Trials have 
demonstrated consistent benefits of dietary fiber on multiple CVD risk factors, 
including serum TG, low-density lipoprotein cholesterol (LDL-C), blood glucose, 
and BP. In hypertensive patients, for example, higher fiber intake reduces systolic 
(S) BP and diastolic (D) BP by 6.0 and 4.2 mm Hg, respectively. Unfortunately, 
few long-term trials have been performed. In the Diet and Reinfarction Trial in 
men with prior MI, advice to consume cereal fiber had no significant effect on 
CHD endpoints, but follow-up was limited to 2 years. In contrast, in long-term 
prospective cohorts, fiber from grains, cereals, and fruits is associated with a lower 
incidence of CHD, and fiber from grains and cereals with a lower incidence of 
DM. Cereal fiber intake may also reduce risk via a substitution effect, replacing 
more refined carbohydrates that may have detrimental effects. 
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Types of Fat  
In contrast to the relatively limited health effects of the proportion of energy 
consumed from total fat, substantial health effects can occur from increases or 
decreases in specific types of fats consumed, either as a replacement for other fats 
or for carbohydrates. Nomenclature schemes and dietary recommendations for fats 
traditionally follow broad chemical classifications defined by the degree of 
unsaturation (e.g., saturated, monounsaturated, polyunsaturated) or the type of 
double bond (e.g., omega[n]-3 or omega[n]-6; . Such broad groupings obscure 
substantial differences in the dietary sources and biologic effects of individual fatty 
acids within each class that can have very specific effects on gene transcription, 
cell membrane fluidity and function, and metabolites generated. As these distinct 
biologic properties are elucidated, clinical and public health focus should focus on 
the types and amounts of individual fatty acids. This chapter follows the 
conventional groupings, but also highlights some effects of individual fatty acids. 
Saturated Fatty Acids  
Meats, dairy products, and tropical oils (e.g., palm, coconut) are major sources of 
saturated fatty acids (SFAs). Based on ecologic comparisons, effects on LDL-C, 
and animal experiments, SFA intake would be expected to increase CHD risk. 
When replacing equivalent calories from carbohydrates, for example, each 1%E 
[66] 
 
greater intake of SFA increases LDL-C by 0.032 mmol/liter. But recent evidence 
seems to suggest otherwise. Lauric acid (12:0), myristic acid (14:0), and palmitic 
acid (16:0) raise  the levels of LDL-C , but stearic acid (18:0) does not seem to 
have this effect. An important thing to note is that since dietary factors affect 
chronic disease via multiple pathways, effects on any single risk marker cannot be 
assumed to translate directly into changes in disease incidence. For example, the 
12-, 14-, and 16-carbon SFAs raise LDL-C compared with carbohydrates, but they 
also lower TG, raise HDL-C, and raise apolipoprotein A-I (apo A-I) levels.SFAs 
also lower lipoprotein(a) when consumed in place of monounsaturated fatty acids 
(MUFAs) or carbohydrates. In the setting of multiple complex lipid and lipoprotein 
changes, effects on a more global lipid risk marker may be most informative. 
These changes suggest minimal effects or even small CHD benefits of SFAs 
compared with carbohydrates. 
Faced with conflicting evidence from risk markers, prospective cohorts and trials 
of disease endpoints may provide better evidence for total clinical effects. In the 
large WHI trial, SFA intake was reduced from approximately 12.5% to 9%E—
largely replaced with carbohydrates—without effects on incident CHD (RR, 0.98), 
stroke (RR, 1.02), total CVD (RR, 0.98), or diabetes (RR, 0.96).
[64,65]
 Similarly, 
two systematic reviews and meta-analyses of prospective cohort studies found no 
significant association between SFA intake and incident CHD 
[66]
.These three large 
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studies indicate no overall effect of SFA consumption on CHD events. Evidence 
from a pooled analysis of individual-level data, including 344,696 men and women 
in 11 prospective cohorts in the United States, Europe, and Israel, suggests that the 
effects of SFAs on CHD may depend on the nutrient replaced. Consuming SFAs in 
place of carbohydrates was associated with lower CHD risk , whereas consuming 
SFAs in place of polyunsaturated fatty acids (PUFAs) was associated with higher 
risk, consistent with some clinical trials . Observational analysis of replacing SFAs 
with MUFAs is limited by their common dietary sources, and no clinical trials of 
CHD events have tested the effects of replacing SFAs with MUFAs. 
These lines of evidence, together with the favorable effects of PUFAs on CVD risk 
factors, suggest that PUFA intake is beneficial in place of SFA or carbohydrates 
(see later), but that replacing SFAs with carbohydrates may cause little benefit or 
even slight harm. Data on effects of carbohydrate (see above) would suggest that 
carbohydrate quality or individual susceptibility to insulin resistance would modify 
this latter effect; indeed, a recent cohort demonstrated that SFA consumption was 
associated with significantly lower CHD risk compared with high-GI (highly 
refined) carbohydrates, similar risk compared with medium-GI carbohydrates, and 
a trend toward higher risk compared with low-GI carbohydrates. Evidence for 
CVD effects of replacing SFAs with MUFAs is mixed (see later). Thus, a focus on 
decreasing SFAs alone may not result in substantial intended CHD  
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Six controlled trials have evaluated the effects of SFA versus various replacement 
nutrients on glucose-insulin homeostasis among individuals predisposed to insulin 
resistance. Three of five trials found improvements in some glucose-insulin 
biomarkers when SFAs were replaced with MUFAs; one of three trials, with 
PUFAs; one trial, with carbohydrate; and zero of two trials, with trans fatty acids 
(TFAs). Four controlled trials have evaluated similar questions among generally 
healthy individuals. Only one of four trials found improvements when SFAs were 
replaced with MUFAs; one of two trials, with carbohydrate; and zero of one trial, 
with PUFAs or TFAs. These mixed findings do not allow robust conclusions on 
the effects of dietary fats on glucose-insulin metabolism; the most promising 
evidence is for potential benefits when SFAs are replaced with MUFAs among 
those predisposed to insulin resistance. In observational studies, circulating or 
tissue SFA biomarkers are often associated with insulin resistance, but endogenous 
SFA levels are increased by both SFA and carbohydrate consumption and also 
altered by lipolysis, lipogenesis, and beta oxidation. SFA intake was lowered in the 
WHI trial without effects on HOMA-IR or incident DM. Among four large 
prospective cohorts evaluating dietary fats and incident DM, none found 
independent associations between SFA or MUFA intake and DM. In contrast, all 
four cohorts found protective associations of PUFAs, vegetable oils, and/or the 
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ratio of PUFA to SFA intake with incident DM. These results point to PUFAs as 
protective against DM, consistent with findings for CHD. 
Evidence for the effects of SFAs on other CVD risk factors or endpoints, such as 
BP or stroke, is limited. Causal mechanisms and independence from other nutrients 
in animal fats and proteins require further study. 
Monounsaturated Fatty Acids  
Animal fats and vegetable oils (e.g., olive and canola) are each major sources of 
MUFAs, largely oleic acid (18:1n-9). Compared with carbohydrates, MUFA intake 
lowers LDL-C and TG, raises HDL-C, and lowers BP. Compared with SFAs, 
MUFA intake lowers LDL-C and raises lipoprotein(a), without substantial change 
in TG or HDL-C. Fewer studies have compared MUFAs and PUFAs; as a 
replacement for carbohydrates, MUFAs may raise HDL-C slightly more and lower 
LDL-C and TG slightly less than PUFAs, with a similar overall improved 
TC/HDL-C ratio. Trials testing the effects of MUFAs on glucose-insulin 
homeostasis have shown mixed results compared with SFA or carbohydrates. Four 
large prospective cohorts have found no relationship between MUFA intake and 
incident DM. 
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Relatively few individual prospective studies have reported on the relationship 
between MUFA consumption and CHD events, with inconsistent results. In a data 
analysed from 11 cohorts, higher MUFA intake, as an isocaloric replacement for 
SFA, was associated with increased risk of cardiovascular disease. In nonhuman 
primates, SFA and MUFA intake were both similarly proatherogenic. No 
randomized controlled trials have tested whether MUFA intake reduces CHD 
events compared with carbohydrates, SFAs, or PUFAs. 
Animal experiments have suggested that MUFAs alter LDL-C particle 
composition, increasing cholesteryloleate content, a change that may increase 
atherogenicity. This could explain why MUFAs lower LDL-C concentrations and 
improve the TC/HDL-C ratio but might not reduce CHD risk. In contrast, 
observational studies and randomized trials have consistently shown that overall 
dietary patterns that have included MUFAs, typically from olive oil as part of an 
overall Mediterranean-type diet, improve CHD risk factors and lower CHD events. 
It is unclear whether these benefits derive from protective effects of MUFAs per 
se, other related components in olive oil (in particular polyphenols in extra virgin 
olive oil), or other factors in the Mediterranean-type dietary pattern. 
Polyunsaturated Fatty Acids  
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Dietary PUFAs can be classified broadly into n-6 PUFAs, largely linoleic acid 
(LA; 18:2n-6) from vegetable oils, and n-3 PUFAs, including alpha-linoleic acid 
(ALA; 18:3n-3) from plant sources (e.g., flaxseed, canola, walnuts, soybeans), and 
eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) 
from fish and shellfish. LA and ALA are essential fatty acids that cannot be 
synthesized by humans. Humans synthesize relatively little EPA and even less 
DHA, so that seafood consumption provides the major source. The ratio of n-6 to 
n-3 fatty acids is not a useful metric of health effects compared with absolute 
consumption levels of these dietary fats. 
Linoleic Acid  
LA typically comprises more than 90% of dietary PUFAs. Compared with 
carbohydrates, LA lowers LDL-C and TG, raises HDL-C, and improves TC/HDL-
C ratio. Effects on other CHD risk markers are less established; some trials have 
suggested that LA may be anti-inflammatory or improve insulin resistance, but 
findings have been mixed. In a pooled analysis from 11 cohorts, greater PUFA 
intake in place of SFAs was associated with a significantly lower incidence of 
CHD. PUFA intake was also associated with lower CHD risk when replacing 
carbohydrates. Consistent with observational studies, a meta-analysis of 
randomized trials that increased total PUFAs or LA in place of SFAs demonstrated 
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reduction in CHD events. No clinical trials have tested whether consuming PUFAs 
in place of carbohydrates or MUFAs reduces CHD events. Overall, the evidence 
suggests that total PUFA or LA intake reduces CHD risk, whether in place of SFAs 
or carbohydrates. Relationships between PUFA intake and DM were discussed 
earlier . 
Alpha-Linoleic Acid  
In some controlled trials, ALA intake has favorably affected some CVD risk 
markers related to platelet function, inflammation, endothelial function, and 
arterial compliance; a meta-analysis of 14 trials found improvements in fibrinogen 
and fasting glucose levels. Whether such effects are caused directly by ALA or by 
its longer-chain metabolites (e.g., EPA) is unclear. Ecologic studies have suggested 
benefits of increasing ALA consumption in populations with low overall n-3 
PUFA intake. Prospective cohorts have shown mixed results, with overall no 
significant relationships seen between ALA intake and CHD events. One trial in 
the 1960s demonstrated no significant change in CHD events with ALA 
supplementation, but follow-up was limited to 1 year. No other trials have tested 
the effects of ALA intake on CHD events, although several trials are planned or 
ongoing. Because ALA is an accessible and inexpensive source of n-3 PUFAs, 
better understanding of its effects is essential. 
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Eicosapentaenoic Acid and Docosahexaenoic Acid  
Controlled trials have demonstrated clear benefits of marine n-3 PUFAs on heart 
rate, BP, and TG levels, and potential benefits on cardiac relaxation and efficiency, 
inflammatory responses, endothelial function, autonomic tone, and urine 
proteinuria. Small trials of prevention of recurrent ventricular tachyarrhythmias in 
patients with implantable cardioverter-defibrillators (ICDs) have yielded 
inconsistent results. Meta-analyses of observational and clinical trial data have 
consistently indicated that longer-chain n-3 PUFAs reduce CHD events, especially 
fatal CHD or arrhythmic death in agreement with evidence from dog and primate 
models for the prevention of ischemia-induced ventricular fibrillation. Four of five 
large randomized controlled trials of fish or fish oil intake have demonstrated 
significant reductions in CHD events. In a meta-analysis of randomized trials, fish 
oil supplementation reduced total mortality by 17% ; these populations were 
generally higher risk, and effects on total mortality should be more modest in 
populations at lower risk of ischemia-induced arrhythmic death. Observational 
studies have suggested benefits for other endpoints, such as nonfatal MI, ischemic 
stroke, and atrial fibrillation, but intervention trials have not established these 
benefits. In a randomized open-label trial in 18,645 Japanese subjects with statin-
treated hypercholesterolemia, the addition of EPA (1.8 g/day for 4.6 years) reduced 
nonfatal coronary events by 19% (P = 0.01). Most studies have assessed combined 
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intakes of EPA plus DHA; insufficient evidence exists to make recommendations 
about EPA versus DHA separately. 
Trans Fatty Acids  
TFA are unsaturated fats with at least one double bond in a trans configuration. 
Major dietary sources are foods made with partially hydrogenated oils, such as 
baked goods, deep-fried foods, packaged snacks, and shortening used for home 
cooking. Ruminant (e.g., cow, sheep, goat) meats and milk contain small amounts 
of TFAs, formed by gut microorganisms. Compared with TFAs from partially 
hydrogenated oils, the low levels of ruminant TFAs consumed  do not appear to 
increase CVD risk appreciably. Higher amounts of TFA intake have clear adverse 
lipid effects, including raising LDL-C, TG, and lipoprotein(a), lowering HDL-C, 
and increasing TC/HDL-C and apo B–to–apo-A-I ratios. In contrast to other 
macronutrients, many of these adverse effects occur regardless of the type of 
nutrient replaced. In controlled feeding trials, consuming 1%E from TFAs in place 
of SFAs, MUFAs, or PUFAs raised the TC/HDL-C ratio by 0.031, 0.054, and 0.67, 
raised apo B by 3.5, 10.0, and 10.9 mg/liter, raised lipoprotein(a) by 3.8, 1.4, and 
1.1 mg/liter, and decreased apo A-I by 7.0, 5.3, and 5.3 mg/liter, respectively. 
Based on controlled trials, observational studies, and animal experiments, TFAs 
may also promote inflammation, endothelial dysfunction, insulin resistance, 
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visceral adiposity, and arrhythmia. The strength of the evidence for these nonlipid 
effects varies, but the implicated pathways suggest an unusual constellation of 
effects on adipocyte dysfunction and insulin resistance. In prospective cohorts, 
small amounts of TFA intake were associated with a substantially higher risk of 
CHD and sudden death .Numerous TFAs exist, each with varying dietary sources 
and biologic and physiologic effects. Emerging evidence suggests that 18-carbon 
TFAs, especially trans-18:2 isomers, may be most adverse. 
Dietary Cholesterol  
Dietary cholesterol raises both LDL-C and HDL-C, with a net increase in total 
cholesterol–to–HDL-C ratio of 0.02 units/100 mg dietary intake. In animal 
experiments, dietary cholesterol is proatherogenic. Long-term prospective studies 
generally have shown no significant associations of dietary cholesterol or selected 
dietary sources (e.g., eggs, shellfish) with incident CVD. Conversely, higher 
cholesterol, egg, or shellfish consumption is associated with a higher incidence of 
DM in five cohorts and with higher CVD risk in patients with established DM in 
three cohorts, suggesting potential interactions between dietary cholesterol, DM 
susceptibility, and CVD that require further study. 
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Protein 
CVD effects of dietary protein have been relatively understudied. In short-term 
trials, protein intake in place of carbohydrates improves BP, TG and LDL-C levels, 
and possibly glycemic control. In the setting of stable weight, higher protein diets 
lower HDL-C when replacing unsaturated fat. In some studies, plant but not animal 
protein sources in diet associate with lower CHD risk, suggesting that types of 
foods consumed or overall diet patterns may be more relevant than protein per se. 
Four cohorts have observed protective associations between animal protein intake 
and risk of hemorrhagic stroke; this emerging relationship requires further study. 
Antioxidants and Vitamins  
B vitamins (e.g., thiamin) are diet-derived, water-soluble, and renally excreted. B 
vitamin deficiency is a known cause of cardiomyopathy (beriberi) in developing 
countries, and emerging evidence suggests that patients with chronic heart failure 
may commonly have lower B vitamin levels. Whether this latter deficiency relates 
to poor nutritional status, diuretic-induced urinary loss, or other metabolic 
causes—or whether replacement improves clinical outcomes—remains unknown. 
Several dietary vitamins and nutrients are associated with lower CVD risk in 
observational studies, but multiple trials of supplements, including folate, B 
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vitamins, beta-carotene, vitamin C, vitamin E, and selenium, have shown no 
significant effects on atherosclerosis progression or CVD events . Many of these 
trials, for reasons of power, evaluated individuals with established CVD or clinical 
risk factors, whereas most observational studies evaluated generally healthy 
individuals. Thus, discrepancies in findings could partly be related to different time 
periods of biologic sensitivity (i.e., some vitamins and nutrients could be important 
only early in the disease course). Such explanations should be considered 
speculative until confirmed in prospective studies and trials. Discrepancies 
between observational studies and supplement trials more likely relate to residual 
bias in observational studies from other lifestyle behaviors (i.e., observed benefits 
are not caused by diet) or because of other nutritional factors (i.e., observed 
benefits are caused by diet but not by the specifically identified vitamins or 
nutrients). Diets higher in beta-carotene and other vitamins, for example, are often 
rich in fruits and vegetables that contain a number of other beneficial factors, 
including other antioxidants, minerals, phytochemicals, and dietary fiber, as well 
as having replacement effects for less healthy foods. Thus, isolating one or even 
several components would unlikely produce similar effects as from consuming the 
whole food, as seen in short-term trials of fruits and vegetables versus 
supplements. 
[78] 
 
Two cohort studies have found that  higher plasma vitamin D levels,  are  
associated with a lower risk of  CVD events.  But various trials involving Vitamin 
D supplementation did not support this finding. Studies involving vitamin D 
supplementation to post menopausal women also did not confer a lower risk for 
cardiovascular events. A meta-analysis of 18 vitamin D trials involving 57,311 
participants showed only a  modest benefit with regard to  total mortality. But the 
question  whether this result was related to fewer deaths from  CVD or cancers, 
which might be prevented by vitamin D, remained unanswered. High plasma 
vitamin D levels may be needed for CVD benefits; But exposure to sun for brief 
periods will provide the required levels of vitamin D. 
Marine n-3 PUFAs are a notable exception to discordance between observational 
studies and supplement trials. Observational studies of habitual fish intake and 
controlled trials of fish oil supplements have shown similar effects on CVD risk 
factors; numerous prospective cohorts of generally healthy individuals have 
demonstrated lower risk of CHD death with fish intake; four of five randomized 
controlled trials in individuals with and without established CHD have 
demonstrated significant reductions in CVD events with fish or fish oil intake; and, 
in a meta-analysis of controlled trials, fish oil supplementation lowered total 
mortality . 
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Flavonoids  
Flavonoids are bioactive polyphenols that include flavonols (in onions, broccoli, 
tea, and various fruits), flavones (in parsley, celery, and chamomile tea), 
flavanones (in citrus fruits), flavanols such as catechins and procyanidins (in 
cocoa, apples, grapes, red wine, and tea), anthocyanidins (in colored berries), and 
isoflavones (in soy). In laboratory experiments and short-term trials, flavonoids 
lower BP and exhibit antioxidant, antiplatelet, and anti-inflammatory effects. In 
trials, intake of cocoa or dark chocolate improves endothelial function and reduces 
SBP and DBP (−5.9 and −3.3 mm Hg). BP lowering occurs with as little as 6.3 g 
(30 kcal)/day of dark chocolate, increases over time, and is related to increased 
endothelial nitric oxide production. This restorative mechanism suggests important 
benefits beyond lowering of BP, because nitric oxide–related endothelial 
dysfunction is fundamental to atherosclerotic and metabolic diseases. A few short-
term trials of other dietary sources (e.g., tea, red wine or grapes) or of specific 
flavonoid extracts have not consistently found improved endothelial function, BP, 
or lipid levels. In prospective cohorts evaluating total or selected dietary flavonoids 
and risk of CVD, 9 of 12 cohorts observed lower CHD death ( 95% CI, 0.71 to 
0.92). Heterogeneity of specific flavonoids and their dietary sources limits 
inference for class effects, but observed lower risk of CHD death plus endothelial 
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and BP benefits of cocoa or dark chocolate provide strong impetus for further 
study. 
 
TABLE- 4 RISK FACTORS AND INTERVENTIONS: 
 
 
 
 
 
 
CLASS RISK FACTOR INTERVENTION 
1 Smoking Smoking cessation 
  Dyslipidemia Lipid management 
  High blood pressure Blood pressure management 
  Preventive medications 
Aspirin, angiotensin-converting enzyme inhibitor, 
beta blocker 
2 Diabetes, prediabetes Diabetes management 
  Physical inactivity Activity management 
  Overweight, obesity Weight management 
  Unhealthy diet, alcohol Improved diet 
  Inflammation Various interventions 
3 
Menopause, hormone replacement 
therapy 
  
  Micronutrients   
  Psychological factors   
  
Novel biochemical and genetic 
markers 
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             MATERIALS AND METHODS 
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MATERIALS AND METHODS: 
This study was an observational cross sectional study conducted in Tirunelveli 
Medical College, Department of  Medicine, during the period from of August 2013 
to August 2014. The aim was to study the symptomatology, the type of  MI, risk 
factors and the outcome at the end of first week in patients with ST elevation 
Myocardial Infarction. The necessary clearances from the concerned departments 
and the ethical committee was obtained prior to the start of the study. 
         All patients admitted to the Intensive Coronary Care Unit in whom a 
diagnosis of ST elevation Myocardial Infarction was made  based on clinical 
features, ECG changes of ST segment Elevation and elevated cardiac biomarkers  
were considered for the study. Patients were included in the study based on 
inclusion and exclusion criteria. 
         An oral consent was taken from all patients for a detailed clinical history and 
examination and the required laboratory  investigations. The details collected from 
each patient was entered in the proforma. (Annexure-1) . 
   The details of the patients regarding age, sex,presentingsymptoms,risk factors 
like smoking, alcohol intake, food habits, diabetes, hypertension, family history of  
coronary artery disease were recorded. The vital signs like pulse and blood 
pressure were recorded and Body mass index was calculated. 
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All the patients were subjected to routine laboratory investigations like Renal 
function tests, Random blood sugar and Lipid profile. Serum Creatinine 
Phosphokinase MB(CPK-MB) levels were also measured. Once the patients 
stabilized, an Echocardiogram was taken and the patient was discharged usually at 
the end of the first week. 
TRIGLYCERIDES : 
Methodology : 
Calorimetric, enzymatic method with glycerophospate oxidase is commonly done . 
This reagent is based on the method of wako and the modifications by McGowan 
et al and Fossati  et al. 
PRINCIPLE : 
Triglycerides +H2O glycerol + free fatty acids 
Glycerol + ATP  Glycerol 3 phosphate + ADP 
Glycerol 3 phosphate + O2 DAP + H2O2 
H2O2 + 4AAP +3,5DHBS Quinoneimine dye + 2H2O 
The intensity of quinoneimine formed is proportional to the triglycerides 
concentration in the sample when measured at 505 nm(500-540nm) 
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 TABLE -5.PROCEDURE : 
Pippette in tubes 
marked 
blank standard test 
Working reagent 1000 ul 1000ul 1000ul 
Distilled water 10ul - - 
Standard - 10ul - 
Sample - - 10ul 
 
Mix and incubate for 10 minutes at 37 degree Celsius, read the absorbance of 
standard and each sample at 505/670 nm on biochromatic analysers against 
reagent blank. 
CALCULATION : 
Triglycerides (mg/dl) = abs of test/abs of standard * concentration of std (mg/dl). 
CHOLESTEROL : 
METHODOLOGY : 
The method is based on the Trinders methodology 
PRINCIPLE ; 
Cholesterol ester + H2O  Cholesterol + fatty acids 
Cholesterol + O2 Cholest-4-en-3-one + H2O2 
2H2O2 + 4AAP + Phenol Quinoneimine dye + 4H2O 
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Absorbance of Quinoneimine so formed is directly proportional to cholesterol 
concentration. 
TABLE-6.PROCEDURE : 
Pippette in tubes 
marked 
blank Standard test 
Working reagent 1000 ul 1000ul 1000ul 
Distilled water 10ul - - 
Standard - 10ul - 
Sample - - 10ul 
 
Mix well and incubate for 5 minutes at 37 degree c or 10 minutes at 20 -25 degree 
c. read the absorbance of the test and standard against reagent blank. 
 
CALCULATION : 
Cholesterol (mg/dl) = abs of test/abs of standard * concentration of std (mg/dl). 
HDL DIRECT : 
The assay is based on a modified polyvinyl sulfonic acid and polyethylene glycol 
methyl ether coupled classic precipitation method with the improvements in using 
optimised quantities of  PVS/PEGME and selected detergents. LDL,VLDL and 
chylomicron react with PVS and PEGME and the reaction results int eh 
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inaccessibility of LDL,VLDL and chylomicron by cholesterol oxidase and 
cholesterol esterase.The enzymes selectively react with HDL to produce H2O2 
which is detected through a trinder reaction. 
HDL + LDL+VLDL+CM  HDL +(LDL+VLDL+CM) + PVS/PEGME 
HDL  fatty acid + H2O2 
2H2O2 + 4-AA +TODB  Quinone +5H2O 
The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for Disease 
Control, Atlanta, USA . 
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OBSERVATIONS AND RESULTS  
          200 patients admitted with clinical features and ECG changes suggestive 
of ST elevation  Myocardial Infarction were enrolled in the study. 
SEX DISTRIBUTION: 
TABLE-7   
 
 
 
 
 
 
 
 
 
 
FIG.10 SEX DISTRIBUTION 
Sex 
Cases 
No % 
Male 155 77.5 
Female 45 22.5 
Total 200 200 
155, 77% 
45, 23% 
MALE FEMALE
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AGE DISTRIBUTION: 
        In the study the youngest patient was a 28 year old male and the oldest patient 
was a 84 year old male.36 cases (18%) were younger than 45 years, the criteria for 
young MI. 164 cases (82%)  were above 45 years.33 cases (16.5%)  had an age 
more than 70 years. The mean age group was 57.7 years. 
 
 
 
 
 
 
 
 
 
 
FIG.11   AGE DISTRIBUTION 
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TABLE-8 AGE DISTRIBUTION 
Age Group 
Cases 
No % 
Upto 40 yrs 22 11.0 
41 – 50 yrs 41 20.5 
51 – 60 yrs 56 28.0 
61 – 70 yrs 48 24.0 
Above 70 yrs 33 16.5 
Total  200 200 
Young Group (<45) 36 18.0 
Old Group (>45) 164 82.0 
Range 28 – 84  yrs 
Mean 57.7  yrs 
SD 12.0  yrs 
 
 
 
 
FIG.12    AGE < 45 YRS  VS.  AGE>45 YRS 
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PRESENTING COMPLAINTS: 
Around 134 patients (67%) came with chest pain as the major complaint.41 
cases(20.5%)  came with giddiness as the main presenting feature. 25 cases came 
with breathlessness as the main complaint. One patient had only sweating as the 
main complaint. Among the 33 cases over 70 years of age, 25 cases (75.7%) had 
giddiness or breathlessness as the presenting feature. 
 
TABLE-9 PRESENTING COMPLAINTS 
 
 
 
 
 
 
 
*One patient had more than one complaint 
Complaints 
Cases 
No % 
Breathlessness 25 12.5 
Chest Pain 134 67.0 
Sweating 1 0.5 
Giddiness 41 20.5 
Total 200* 200 
[92] 
 
FREQUENCY OF SYMPTOMS AMONG PATIENTS: 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.13   FREQUENCY OF SYMPTOMS 
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VITAL SIGNS: 
The mean pulse rate of  the group was around 82.2 with a lowest being 42/min and 
the highest being 116/min. The mean Systolic BP was 140.4 mm Hg with a range 
between 80 mm Hg and 190 mm Hg. The mean diastolic BP was 86.5 mm Hg with 
a range between 50 mm Hg and 130mm Hg. 
 
 
 
 
 
 
 
 
 
 
FIG.14    VITAL SIGNS 
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TABLE-10 VITAL SIGNS 
Variable Range Mean SD 
Pulse Rate 42 - 116 82.2 16.0 
Systolic BP 80 - 190 140.4 28.5 
Diastolic BP 50 - 130 86.5 15.8 
 
FOOD HABITS: 
 
 
 
 
 
 
 
FIG.15   FOOD HABITS 
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TABLE-11   FOOD HABITS 
Food Habit 
Cases 
No % 
Vegetarian 32 16.0 
Non Vegetarian 168 84.0 
Total 200 200 
 
32 cases (16%) of the study group were vegetarian; the remaining 168 cases (84%) 
being non vegetarian. 
BODY MASS INDEX: 
 
 
 
 
 
 
FIG.16   BODY MASS INDEX 
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TABLE-12 BODY MASS INDEX OF PATIENTS 
 
BMI 
Cases 
No % 
Normal (18 – 25) 106 53.0 
Over weight (25 – 30) 82 41.0 
Obese Class I (30 – 35) 11 5.5 
Obese Class II (35 – 40) 1 0.5 
Total  200 200 
Range 18.3 – 35.15 
Mean 25.57 
SD 3.13 
 
106 cases (53%) had a normal BMI with 82 (41%) of them being in the overweight 
category.12 cases (6%) belonged to the obese category. The mean body mass index 
is around 25.6 with a range from 18.3 to 35.15  
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BLOOD SUGAR/UREA/CPK-MB LEVELS:  
The average blood sugar value was 152.7 mg% with a range between 60 mg %and 
321 mg%. The mean urea values were 35.9 mg% and CPK-MB was 36.7 IU/L 
TABLE-13 SUGAR /UREA/CPK-MB OF PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
FIG.17 MEAN VALUES OF SUGAR/UREA/CPK-MB 
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LIPID PROFILE: 
TABLE-14 LIPID PROFILE OF PATIENTS. 
Variable 
Normal Cases Abnormal cases Values 
No. % No. % Range Mean SD 
Total Cholesterol 188 94.0 12 6.0 85 – 246 164.1 28.3 
HDL 13 6.5 187 93.5 16 – 48 32.3 6.5 
LDL 183 91.5 17 8.5 50 – 168 104.5 22.0 
TGL 199 99.5 1 0.5 60 - 204 137.3 33.6 
 
The mean cholesterol values were 164 mg% with a range between 85 and 
246mg%;mean HDL values being 32.3 mg%. The mean LDL value was around 
104 mg% which is normal with a range between 50 and 168 mg%. The LDL 
cholesterol values were normal in majority of the individuals in this study with the 
HDL being low in majority of the individuals. The mean Triglyceride levels were 
around 137 mg%. 
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TOTAL CHOLESTEROL/ HDL /LDL / TGL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.18 TOTAL CHOLESTEROL/ HDL /LDL / TGL 
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RISK FACTORS: 
The risk factors were studied in all the 200 patients. 
TABLE -15 RISK FACTORS AMONG PATIENTS 
Risk Factors 
Present Absent 
No. % No. % 
Smoking(among males- n=155)  120 77.4 35 22.6 
Alcoholism(among males- n=155) 108 69.7 47 30.3 
Physical Inactivity 96 48.0 104 52.0 
Diabetes 74 37.0 126 63.0 
Hypertension 66 33.0 134 67.0 
Family History of CAD 65 32.5 135 67.5 
 
Among the 155 males in the study, 77.4%   were smokers and 69.7% consumed 
alcohol on a regular basis. None of the females had history of smoking and alcohol 
intake. Surprisingly only 37% in the group had diabetes. Hypertension was found 
in 33% of cases. Around 32.5% gave a positive family history of CAD. 
Risk factors were different for Young MI (< 45 yrs). 91.7% were smokers, 88.9% 
consumed alcohol, around 50%  had  positive family history; 47% were leading a 
[101] 
 
sedentary life style and everyone 100% had low HDL. Around 16% were diabetic 
and 22% were hypertensive. 
 
 TABLE-16   RISK FACTORS IN YOUNG MI 
RISK 
FACTORS 
Young age group (n=36) 
No % 
Smoking 33 91.7 
Alcoholism 32 88.9 
Physical 
inactivity 
17 47.2 
Diabetes 6 16.7 
Hypertension 8 22.2 
Family 
History 
18 50.0 
Abnormal 
HDL 
36 100 
Abnormal 
LDL 
4 11.1 
Diet Veg 1 2.8 
Non Veg 36 97.2 
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TYPE OF MYOCARDIAL INFARCTION: 
TABLE -17   MI TYPES AMONG PATIENTS: 
Myocardial Infarction Type 
Cases 
No % 
Anterior wall 44 22 
Antero lateral 3 1.5 
Anteroseptal 29 14.5 
Extensive Anterior Wall 29 14.5 
Inferior wall 51 25.5 
Inferoposterior wall 26 13.0 
Lateral wall 8 4.0 
Inferolateral&RVMI 10 5.0 
Total 200 200 
 
Among the MI types Inferior wall (25.5%) and Anterior wall (22%) were the most 
common types .Inferolateral, Anterolateral and Right Ventricular MI were 
comparatively less commonly observed in this study. 
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FIG.19   THE TYPES OF MI SEEN AMONG PATIENTS 
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TIMI RISK SCORE : 
 
 
 
 
 
 
 
 
 
FIG.20 TIMI RISK SCORE 
Among the 200 patients,124 cases (62%) had a TIMI Risk score of 1 to 4, 54 cases 
(27%) had a TIMI risk score of 5 to 8, 22 cases (11%) had a TIMI risk score of 9 
and above. 
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TABLE-18  TIMI RISK SCORE 
TIMI  Score 
Cases 
No % 
1 - 4 124 62.0 
5 - 8 54 27.0 
9 & Above 22 11.0 
Range 0 – 12 
Mean 4.29 
SD 2.7 
 
 
ECHO STUDY: 
Among the 182 people in whom ECHO was done,36 cases (19.8%) had normal LV 
function,130 cases (71.4%) had mild LV dysfunction, 13 cases (7.1%) had 
moderate LV dysfunction and 3 cases (1.7%) . 
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TABLE -19 ECHO STUDY 
Echo Result 
Cases 
No % 
Normal LV Function 36 19.8 
Mild LV Dysfunction 130 71.4 
Moderate Dysfunction 13 7.1 
Severe Dysfunction 3 1.7 
Total 182 100 
 
 
 
 
 
 
 
 
FIG. 21 ECHO RESULTS 
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OUTCOME: 
TABLE-20 OUTCOME OF PATIENTS AT THE END OF FIRST WEEK 
Out Come 
Cases 
No % 
Discharged alive 182 91.0 
Death 18 9.0 
Total 200 100 
 
 
 
 
 
 
 
FIG.22   OUTCOME AT THE END OF ONE WEEK 
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TIMI RISK SCORE AND OUTCOME: 
TABLE -21 RELATIONSHIP BETWEEN TIMI SCORE AND OUTCOME 
TIMI risk 
score and 
Outcome 
TIMI Risk 
Score 
 No of 
Cases 
Out Come 
Discharged alive Death 
No % No % 
1 - 4 124 124 100 - - 
5 - 8 54 50 92.6 4 7.4 
9 & Above 22 8 36.4 14 63.6 
Mean Time Risk Score 
SD 
3.8 
2.25 
9.28 
1.67 
„p‟ <0.0001 Significant 
 
All the patients (124 cases) who had a TIMI risk score of 1 to 4 survived at the end 
of first week, in the 54 patients with a TIMI risk score of 5 to 8, 50 patients 
survived at the end of first week. The percentage of mortality was 7.4%. In the 22 
patients with a TIMI score of 9 and above, 14 expired at the end of first week with 
a mortality of 63.6%. The association is statistically significant. 
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FIG.23   TIMI SCORE AND OUTCOME 
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                           DISCUSSION 
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DISCUSSION: 
      Coronary Artery Disease is an important cause of death in the world. The 
symptoms of Coronary artery disease vary from exertional chest pain due to Stable 
Angina to Sudden death due to ventricular fibrillation. Since data regarding risk 
factors has been largely been derived from developed countries this study has been 
done with regard to risk factors in the predominantly rural population. 
   Coronary artery Disease is more common among males.  In our study, males 
accounted for 77.5% of the cases(155 cases) and females accounted for 22.5% of 
the cases(45 cases).The incidence of Coronary artery disease increases after the 
fourth decade of life. In our study, majority of the patients (68.5%) were above the 
age of fifty years. With regard to the presenting complaints, though chest pain was 
the most common presenting complaint in majority of individuals (67%), around 
75% of the patients above 70 years of age, breathlessness and giddiness was the  
major presenting complaint. This may be due to the fact that elderly have poor pain 
perception and hence do not present with chest pain
[67] 
. 
    Though the incidence of Myocardial Infarction is said to increase with each 
decade , in our study only 16.5 % of cases were above 70 years of age. Goyal et 
al
[68] 
 found that 52% of the Cardiovascular deaths in India were below 70 years. In 
our study 83.5% of cases were below 70 years. This may be due to the sample size 
[112] 
 
of the study. This might also be due to the fact that Elderly Patients usually have 
multiple co morbidities and may have expired before coming to a referral centre. 
Patients with Coronary Artery disease have multiple risk factors both modifiable 
and non modifiable. Men above 45 years and Women above 55 years, Old age, 
positive family history, race are non-modifiable risk factors. Diabetes mellitus, 
hypertension, dyslipidemia, smoking, metabolic syndrome, physical inactivity 
appear to be modifiable risk factors. 
Among the 155 males in the study, 77.4%   were smokers and 69.7% gave history 
of excess alcohol intake. Excess consumption of tobacco in varied forms may be a 
leading cause of coronary artery disease in the lower socioeconomic group
[69] 
. In 
our study, diabetes was found in 37% of the cases and hypertension in 33% of the 
cases. In our study, 41% belonged to the overweight category with just 6% 
belonging to the obesity category. This may be due to the fact that many patients 
belong to the poor socioeconomic status and also due to the fact that the patients 
may have had abdominal obesity. Positive family history was found in 32.5% of 
the cases. 
          In Young MI (<45 years), 91.7% were smokers, 88.9% consumed alcohol,  
around 50%  had  positive family history; 47% were leading a sedentary life style 
and everyone 100% had low HDL. 
[113] 
 
   Inferior wall MI (25.5%)  and Anterior wall MI (22%) were the most common 
types of MI that were seen. Among the 200 patients, 91% were discharged alive 
and 9% expired. The most common cause of death was cardiogenic shock. Among 
the 18 patients who expired, 14 patients had a Thrombolysis in Myocardial 
Infarction(TIMI) risk score of  9 and above  and the remaining four had a TIMI 
score of  5 to 8. mortality was not seen in those with a TIMI risk score of below 
five. The association was statistically significant ( p<0.0001).  
             Among the survivors around 72% of them had mild LV dysfunction, 
around  20% had normal LV function. 7.1% of patients had moderate LV 
dysfunction and 1.7%  had severe LV dysfunction. 
 There may be many shortcomings in this study. But this study will definitely give 
us a fair idea of the risk factors for MI in the rural Indian population.    
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                            SUMMARY 
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SUMMARY: 
In our study, it was found, 
 Males were more commonly affected than females 
 Age group above 50 years was most commonly affected 
 Majority of individuals belonged to 51-60 years age bracket 
 Chest pain was the most common presenting complaint, but in individuals 
above 70 years  breathlessness and giddiness were more common 
 Smoking and excess alcohol intake were the major contributors followed by 
diabetes and hypertension 
 Inferior Wall MI and Anterior Wall MI were the most common MI types 
seen. 
 Patients with higher TIMI risk score had increased mortality. 
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                              CONCLUSION  
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CONCLUSION: 
Coronary Artery Disease continues to exact a heavy toll on the Indian population. 
Though significant strides have been made in the field of interventional cardiology 
like angioplasty, pacemakers, implantable cardioverter defibrillators, etc many of 
these advances are yet to reach the masses. The need of the hour is to implement 
strict preventive measures which include health education, legislative measures 
like banning smoking in public places and enforcing them strictly, emphasizing the 
importance of a healthy diet and an active lifestyle. These measures may help in 
the long run in reducing the burden of cardiovascular diseases in our country.  
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                                       ANNEXURE-1 
PROFORMA 
CLINICAL PROFILE OF PATIENTS WITH MYOCARDIAL 
INFARCTION 
PATIENT INFORMATION SHEET 
NAME:                                            AGE/SEX:                   IP NO:       
DATE AND TIME OF ADMISSION: 
PRESENTING COMPLAINTS: 
 
 
 
PR:                                            BP: 
HT:                      WT:               BMI: 
ECG: 
MI TYPE: 
LIPID PROFILE: TC:             HDL:            LDL:                   
                                VLDL:               TGL: 
BLD SUGAR:                      UREA:             CREATININE: 
FAMILY HISTORY:                          CKD: 
 
CARDIAC MARKERS: CPK-MB 
 
[131] 
 
ECHO: 
CHAMBERS: 
VALVES: 
LV FUNCTION: 
REGIONAL WALL MOTION ABNORMALITY: 
IVS(d)/LVDd/LVDs/EF: 
CLOT/PERICARDIAL EFFUSION: 
RISK FACTORS: 
SMOKING  
ALCOHOL  
FOOD HABITS  
OBESITY  
PHYSICAL INACTIVITY  
DIABETES  
HYPERTENSION  
 
TIMI RISK SCORE - STEMI 
RISK FACTORS POINTS 
DM/HT/HISTORY OF ANGINA  
SYSTOLIC BP<100mm HG  
HEART RATE>100/MIN  
KILLIP CLASS II-IV  
BODY WT<67 KG  
ANTR ST ELEVATION/LBBB  
TIME TO TREAT > 4 HRS  
AGE > 75 YRS  
AGE 65-74 YRS  
 
ANNEXURE-2 
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                                                                                                               CLINCIAL PROFILE OF PATIENTS WITH MYOCARDIAL INFARCTION                                                                                                                                                                                                                                                                                                                                                     
S.NO NAME AGE /SEX COMPLAINTS PULSE BP MI TYPE BMI SMOKER ALCOHOLIC FOOD HABITS OBESITY PHYSICAL INACTIVITY DIABETES HYPERTENSION FAMILY HISTORY OF CAD SUGAR UREA CREATININE TC/HDL/LDL/TGL CPK MB TIMI SCORE ECHO OUTCOME
1 MUTHU 37/M CHEST PAIN 72 160/100 INFERIOR WALL 23.2 YES YES NON VEG NO NO NO YES NO 119 34 0.7 131/34/66/151 29.6 3 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
2 KANAGARAJ 74/M GIDDINESS 70 110/70 INFEROPOSTERIOR WALL 23 NO NO NON VEG NO YES NO NO NO 98 24 0.8 120/24/76/106 30.5 4 MILD LV DYSFUNCTION/46% DISCHARGED
3 VIJAYARAJ 47/M CHEST PAIN,SWEATING 80 90/70 ANTERIOR WALL 21.7 YES YES NON VEG NO NO NO NO YES 66 18 1 121/29/67/125 32.2 4 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
4 ESWARAN 60/M BREATHLESSNESS 76 110/70 INFERIOR/RV MI 23.4 NO NO NON VEG NO NO NO NO YES 109 34 1.5 166/30/120/83 33.3 2 MILD LV DYSFUNCTION/46% DISCHARGED
5 MOOSA 57/M GIDDINESS 94 120/80 INFERIOR WALL 24.4 NO NO NON VEG NO YES NO NO YES 113 50 1.1 113/27/60/132 27.6 1 NORMAL LV FUNCTION/58% DISCHARGED
6 MADASAMY 67/M CHEST PAIN 76 140/100 EXTENSIVE ANTERIOR WALL 25.5 NO NO NON VEG YES YES YES YES YES 160 22 0.9 130/16/98/80 28.4 8 MILD LV DYSFUNCTION/40%/LVH DISCHARGED
7 SHEIKH 50/M CHEST PAIN 98 160/100 EXTENSIVE ANTERIOR WALL 30.79 YES YES NON VEG YES YES YES YES NO 116 40 0.8 180/40/108/160 29.9 3 MILD LV DYSFUNCTION/46% DISCHARGED
8 SANKARNARAYAN 46/M CHEST PAIN 106 160/110 INFERIOR WALL 22.83 YES YES NON VEG NO NO YES YES NO 146 50 0.7 186/30/126/146 29.1 4 NORMAL LV FUNCTION/60% DISCHARGED
9 SUNDARAMMAL 70/F GIDDINESS 42 80/60 INFERIOR WALL 28.6 NO NO NON VEG YES YES YES YES NO 188 41 1.1 188/46/110/160 38.6 9 DEATH
10 MURUGAN 45/M CHEST PAIN 94 160/100 ANTERIOR WALL 23.24 YES YES NON VEG NO NO NO NO NO 106 42 0.6 180/29/126/125 34.8 4 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
11 DEVAKI 60/F CHEST PAIN 64 180/110 INFERIOR WALL 31.64 NO NO NON VEG YES YES YES YES NO 146 34 0.6 200/40/130/146 32.7 3 NORMAL LV FUNCTION/54%/LVH DISCHARGED
12 SAILAPPAN 77/M BREATHLESSNESS 62 170/100 INFEROPOSTERIOR WALL 21.8 YES YES NON VEG NO NO NO YES NO 133 37 1.1 188/42/126/100 37.5 6 NORMAL LV FUNCTION/54%/LVH DISCHARGED
13 BALAKRISHNAN 28/M CHEST PAIN 90 150/100 ANTERIOR WALL 29 YES YES NON VEG YES YES NO NO NO 116 23 0.8 166/34/116/80 36.4 4 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
14 KANNAN 40/M BREATHLESSNESS 96 150/100 ANTERIOR WALL 30.5 YES YES NON VEG YES YES NO NO NO 96 19 0.9 160/32/102/136 32.2 3 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
15 RANGANATHAN 61/M CHEST PAIN 106 160/100 EXTENSIVE ANTERIOR WALL 29.7 YES YES NON VEG YES YES YES NO NO 186 47 1.1 196/40/116/200 40.9 7 MODERATE LV DYSFUNCTION/32%LVH DISCHARGED
16 RAJASEKAR 52/M CHEST PAIN 90 180/110 EXTENSIVE ANTERIOR WALL 30.4 YES YES NON VEG YES YES NO YES YES 118 42 1 170/30/104/180 32.6 5 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
17 NARAYANAN 76/M BREATHLESSNESS 104 180/110 ANTERIOR WALL 27.66 NO NO VEG YES NO NO YES NO 130 58 1.3 184/32/112/194 33.7 10 MODERATE LV DYSFUNCTION/38%/LVH DISCHARGED
18 POOMANI 58/F CHEST PAIN 104 80/60 EXTENSIVE ANTERIOR WALL 31.6 NO NO NON VEG YES YES YES NO NO 230 70 1.5 190/28/126/186 41.1 10 DEATH
19 LILY PUSHPAM 58/F CHEST PAIN 62 160/100 INFEROPOSTERIOR WALL 31.6 NO NO VEG YES YES NO YES NO 146 36 0.7 146/22/108/80 29.2 1 NORMAL LV FUNCTION/56%/LVH DISCHARGED
20 NAMBIRAJAN 50/M CHEST PAIN 94 180/100 EXTENSIVE ANTERIOR WALL 29.6 NO NO NON VEG YES YES YES NO YES 198 40 1.3 174/30/114/156 39.4 5 MODERATE LV DYSFUNCTION/38%/LVH DISCHARGED
21 PETCHIAMMAL 64/F CHEST PAIN 106 160/90 EXTENSIVE ANTERIOR WALL 31.26 NO NO VEG YES YES YES NO NO 174 41 1.2 136/30/78/144 30.3 9 MILD LV DYSFUNCTION/49% DISCHARGED
22 PONNUSAMY 67/M GIDDINESS 96 170/100 ANTEROSEPTAL 23.6 YES NO NON VEG NO NO YES NO YES 194 60 1.4 144/22/84/190 32.1 7 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
23 SEETHALAKSHMI 72/F CHEST PAIN 104 120/70 ANTERIOR WALL 35.15 NO NO NON VEG YES YES YES NO NO 284 50 0.9 182/42/100/198 34.2 9 MODERATE LV DYSFUNCTION/32%LVH DISCHARGED
24 MADAKANNU 71/M BREATHLESSNESS 78 160/100 INFERIOR WALL 22.6 NO NO NON VEG NO NO YES NO NO 180 36 1.4 194/36/124/174 29.8 3 NORMAL LV FUNCTION/52%/LVH DISCHARGED
25 SUBRAMANIAN 62/M GIDDINESS 64 120/70 INFERIOR WALL 28.2 NO NO NON VEG YES YES YES NO NO 183 44 1.4 136/28/88/100 34.5 1 NORMAL LV FUNCTION/54%/LVH DISCHARGED
26 GANESH 48/M CHEST PAIN 74 130/70 INFERIOR WALL 21.22 YES NO NON VEG NO YES NO NO NO 110 22 0.9 156/32/90/170 38.8 1 NORMAL LV FUNCTION/56%/LVH DISCHARGED
27 MARIAPPAN 36/M BREATHLESSNESS 103 160/110 ANTEROSEPTAL 22.15 YES NO NON VEG NO NO NO NO NO 85 35 0.8 192/32/140/102 40.7 6 MILD LV DYSFUNCTION/48% DISCHARGED
28 MOOKAMAL 75/F CHEST PAIN 105 110/70 ANTERIOR WALL 29.1 NO NO VEG YES YES YES NO NO 180 49 1.1 146/34/80/166 37.7 9 MILD LV DYSFUNCTION/45% DISCHARGED
29 MURUGAIH 63/M BREATHLESSNESS 80 110/70 ANTEROSEPTAL 22.7 YES YES NON VEG NO NO NO NO YES 140 48 1.4 210/32/150/140 36.6 4 MILD LV DYSFUNCTION/48% DISCHARGED
30 ANTONY JOSEPH 48/M BREATHLESSNESS 98 160/90 EXTENSIVE ANTERIOR WALL 23.6 YES YES NON VEG NO NO NO YES NO 106 46 1.4 184/40/120/120 43.8 6 SEVERE LV DYSFUNCTION/29%/LV DILATED DISCHARGED
31 SELVARAJ 65/M CHEST PAIN 48 100/60 INFEROPOSTERIOR WALL 23.1 YES NO NON VEG NO NO NO NO YES 144 31 1.5 122/25/72/126 40.1 7 MILD LV DYSFUNCTION/43% DISCHARGED
32 UCHIMAKALI 45/F CHEST PAIN 90 150/90 INFERIOR WALL 23.9 NO NO NON VEG NO YES YES YES NO 163 31 0.9 160/33/106/104 38.7 5 MILD LV DYSFUNCTION/45% DISCHARGED
33 MURUGAN 53/M BREATHLESSNESS 64 170/100 EXTENSIVE ANTERIOR WALL 23.3 YES YES NON VEG NO NO NO NO YES 87 23 0.9 164/18/110/180 41.9 2 MODERATE LV DYSFUNCTION/32%LVH DISCHARGED
34 RAJAMMAL 70/F BREATHLESSNESS 96 160/90 ANTEROSEPTAL 22.8 NO NO NON VEG NO NO NO NO NO 106 49 0.7 190/42/120/140 37.2 5 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
35 ARUMUGAM(D) 50/M CHEST PAIN 108 90/60 ANTEROSEPTAL 22.2 YES YES NON VEG NO NO NO NO NO 105 48 1.1 176/24/116/184 49.7 10 DEATH
36 VALAYAPANDIAN 55/M GIDDINESS 78 150/100 INFEROPOSTERIOR WALL 21.2 NO NO NON VEG NO NO NO NO NO 91 16 0.8 151/30/106/88 36.9 1 NORMAL LV FUNCTION/61% DISCHARGED
37 CHELLADURAI 38/M CHEST PAIN 86 160/100 ANTERIOR WALL 21.5 YES YES NON VEG NO YES NO NO YES 109 30 1.4 172/38/116/90 34.9 2 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
38 SUBRAMANIAM 55/M CHEST PAIN 94 180/100 ANTEROSEPTAL 22.1 YES YES VEG NO YES NO YES YES 106 39 0.7 192/36/120/180 29.4 5 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
39 KANNAN 53/M CHEST PAIN 75 150/90 ANTEROSEPTAL 22.6 YES YES NON VEG NO NO NO NO YES 68 18 0.8 134/28/80/130 36.1 4 MILD LV DYSFUNCTION/40% DISCHARGED
40 KALIMUTHU 47/M GIDDINESS 56 100/70 INFERIOR WALL 25.9 YES YES NON VEG YES YES YES NO NO 197 34 1.4 182/40/112/149 32.7 7 NORMAL LV FUNCTION/60% DISCHARGED
41 RAHEEMA 63/F CHEST PAIN 116 80/60 EXTENSIVE ANTERIOR WALL 29.9 NO NO NON VEG YES YES YES YES NO 199 44 0.7 152/30/100/110 46.7 10 DEATH
42 CHANDRAMOHAN 37/M GIDDINESS 80 140/90 INFERIOR WALL 26.2 YES YES NON VEG YES YES NO NO YES 106 43 1.1 160/38/106/80 38.6 3 NORMAL LV FUNCTION/58% DISCHARGED
43 NATHAN 54/M CHEST PAIN 50 110/70 INFERIOR WALL 33.2 NO NO NON VEG YES YES YES NO YES 307 24 1.4 210/29/160/107 30.7 4 MILD LV DYSFUNCTION/45% DISCHARGED
44 MARIAMMAL 79/F GIDDINESS 96 80/60 ANTERIOR WALL 28.6 NO NO NON VEG YES YES YES YES NO 219 40 1.5 240/36/160/180 40.9 11 DEATH
45 KUMARAVEL 40/M CHEST PAIN 82 140/90 ANTERIOR WALL 29.4 NO NO NON VEG YES YES YES YES YES 248 23 1.2 199/39/140/104 36.7 4 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
46 NATCHATHIRAM 50/F CHEST PAIN 90 130/90 EXTENSIVE ANTERIOR WALL 27.1 NO NO NON VEG YES NO NO NO YES 101 28 0.6 103/22/61/99 38.6 4 MODERATE LV DYSFUNCTION/32%LVH DISCHARGED
47 MARIAPPAN 55/M CHEST PAIN 80 100/80 INFEROPOSTERIOR WALL 32 YES YES NON VEG YES YES YES NO YES 217 17 1.2 126/22/70/174 39.7 4 MILD LV DYSFUNCTION/47%/LVH DISCHARGED
48 PERUMAL 57/M CHEST PAIN 62 110/60 INFERIOR WALL 27.2 YES YES NON VEG YES YES NO YES NO 270 23 0.9 128/30/70/142 39.1 2 NORMAL LV FUNCTION/56% DISCHARGED
49 ANANTHRAM(D) 55/M CHEST PAIN 108 90/60 ANTERIOR WALL 22.8 YES YES VEG NO NO NO NO YES 98 52 1.3 180/21/123/190 36.5 11 DEATH
50 MARIAKUTTY 39/M CHEST PAIN 66 140/90 INFERIOR WALL 28.3 YES YES NON VEG YES YES NO NO NO 147 25 1.2 108/24/68/145 29.9 1 NORMAL LV FUNCTION/61% DISCHARGED
51 AYYADURAI 34/M BREATHLESSNESS 70 100/70 EXTENSIVE ANTERIOR WALL 27.7 YES YES NON VEG YES YES NO NO YES 80 21 1 116/20/80/84 30.2 5 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
52 NATARAJAN 65/M BREATHLESSNESS 78 120/80 ANTEROSEPTAL 28.7 NO NO NON VEG YES YES NO NO NO 97 20 0.7 85/16/54/76 34.3 3 MILD LV DYSFUNCTION/45% DISCHARGED
53 JAGADHEESH 40/M CHEST PAIN 75 130/90 INFEROPOSTERIOR WALL 27.6 YES YES NON VEG YES NO NO NO YES 210 16 0.9 186/34/131/113 33.8 0 NORMAL LV FUNCTION/56% DISCHARGED
54 JEYARAJ(D) 56/M CHEST PAIN 60 80/60 EXTENSIVE ANTERIOR WALL 26.9 YES YES NON VEG YES YES YES NO YES 260 26 1.4 133/24/70/196 42.4 7 DEATH
55 CHELLIAH 64/M CHEST PAIN 78 130/70 INFEROPOSTERIOR WALL 27.3 YES YES NON VEG YES YES NO NO NO 159 34 1.5 134/32/80/110 37.9 1 NORMAL LV FUNCTION/56%/LVH DISCHARGED
56 BEER MYDEEEN 34/M CHEST PAIN 66 110/70 INFERIOR WALL 27.6 YES YES NON VEG YES YES NO NO NO 136 16 0.8 172/38/108/80 33.3 1 MILD LV DYSFUNCTION/49% DISCHARGED
57 PERUMAL 65/F CHEST PAIN 96 180/100 ANTERIOR WALL 29.4 NO NO NON VEG YES YES NO NO NO 69 24 0.9 166/30/116/98 38.4 6 MILD LV DYSFUNCTION/45% DISCHARGED
58 RAJESHWARI 52/F CHEST PAIN 92 170/100 LATERAL WALL 28.8 NO NO NON VEG YES YES NO YES NO 124 18 0.6 166/26/100/196 28.7 4 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
59 SINGARAJ 45/M BREATHLESSNESS 86 120/80 ANTEROSEPTAL 27.1 YES YES NON VEG YES YES YES NO YES 171 19 1 100/29/50/102 29.1 4 MILD LV DYSFUNCTION/45% DISCHARGED
60 MUTHAIAH 75/M BREATHLESSNESS 88 110/60 ANTERIOR WALL 27.8 YES YES NON VEG YES NO NO NO NO 88 37 1.3 190/38/126/130 35.7 7 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
61 PETCHI 60/M GIDDINESS 78 130/80 INFERIOR/RVMI 23.3 YES YES NON VEG NO NO YES YES NO 160 29 1 138/26/78/173 35.5 1 NORMAL LV FUNCTION/56% DISCHARGED
62 KOMBAN 40/M CHEST PAIN 82 190/130 EXTENSIVE ANTERIOR WALL 24.9 NO NO NON VEG NO NO NO YES YES 138 49 1.5 180/38/110/160 43.9 5 MODERATE LV DYSFUNCTION/32%LVH DISCHARGED
63 ESAKKI 49/M CHEST PAIN 80 120/90 INFERIOR WALL 24.6 YES YES NON VEG NO NO NO NO YES 60 24 1.1 134/24/92/90 36.8 1 MILD LV DYSFUNCTION/49% DISCHARGED
64 MEENAMMAL(D) 55/F CHEST PAIN 104 80/50 EXTENSIVE ANTERIOR WALL 28.8 NO NO NON VEG YES YES YES NO NO 186 50 1.3 216/36/140/200 48.8 10 DEATH
65 PACKIARAJ 76/M GIDDINESS 70 130/80 INFERIOR WALL 24.4 YES NO NON VEG NO NO NO NO NO 144 40 1 148/30/90/140 34.5 4 MILD LV DYSFUNCTION/44% DISCHARGED
66 MARIAPPAN 59/M CHEST PAIN 106 130/90 LATERAL WALL 24.5 YES YES NON VEG NO NO NO NO NO 116 30 0.8 106/20/74/60 32.7 7 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
67 SUDALIMUTHU 47/M CHEST PAIN 88 110/70 EXTENSIVE ANTERIOR WALL 24.2 YES NO NON VEG NO NO NO YES 110 43 1.2 108/28/60/100 39.7 3 MILD LV DYSFUNCTION/49% DISCHARGED
68 RAMAN 75/M GIDDINESS 78 140/100 HIGH LATERAL MI 23.8 YES YES NON VEG NO NO NO NO NO 157 42 1.5 139/39/76/136 35.6 3 MILD LV DYSFUNCTION/45% DISCHARGED
69 PALAVESAM 54/M BREATHLESSNESS 86 130/70 ANTEROSEPTAL 24.9 NO NO VEG NO NO NO NO YES 102 26 1.1 120/36/64/100 35.9 1 NORMAL LV FUNCTION/56% DISCHARGED
70 GANESAN 40/M BREATHLESSNESS 60 130/90 ANTEROLATERAL 24.7 NO YES VEG NO NO NO NO NO 114 18 0.7 156/36/95/124 39.8 2 MILD LV DYSFUNCTION/49% DISCHARGED
71 SELVARAJ(D) 74/M GIDDINESS 54 80/60 INFEROPOSTERIOR WALL 23.2 YES YES NON VEG NO YES YES NO NO 236 52 1.1 126/26/80/104 47.5 9 DEATH
72 MASOODH 63/M CHEST PAIN 64 160/100 INFERIOR WALL 24.7 YES NO NON VEG NO NO NO NO YES 188 49 1 123/20/83/106 30.6 1 NORMAL LV FUNCTION/69% DISCHARGED
73 BEER MOHAMMED 64/M CHEST PAIN 60 120/70 INFERIOR WALL 24.6 YES NO NON VEG NO YES YES YES YES 160 39 1.3 156/25/110/104 35.5 2 NORMAL LV FUNCTION/57% DISCHARGED
74 MARIYA ANTONY 56/M GIDDINESS 66 160/100 INFERIOR WALL 24.4 NO YES NON VEG NO NO YES NO NO 242 33 1.1 160/26/102/168 26.7 1 NORMAL LV FUNCTION/61% DISCHARGED
75 MOHD.ABU BAKR 39/M CHEST PAIN 96 150/100 ANTEROSEPTAL 24.7 YES YES NON VEG NO YES NO NO YES 147 41 1.3 218/38/144/180 33.6 1 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
76 THALAVAI 75/M BREATHLESSNESS 94 170/110 ANTERIOR WALL 24.4 NO NO NON VEG NO NO NO YES NO 94 44 0.7 146/30/100/80 34.7 5 NORMAL LV FUNCTION/62%/LVH DISCHARGED
77 RAMASAMY 68/M CHEST PAIN 68 100/70 INFEROPOSTERIOR WALL 24.7 YES YES NON VEG NO NO NO YES YES 96 38 1.1 168/33/110/126 39.1 5 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
78 VELAMMAL 48/F CHEST PAIN 54 90/60 INFEROPOSTERIOR WALL 31.1 NO NO VEG YES YES YES NO NO 149 50 1.1 166/36/90/200 43.2 7 DEATH
79 PALANI SELVAM 55/M CHEST PAIN 78 160/100 EXTENSIVE ANTERIOR WALL 24.1 YES NO NON VEG NO NO NO NO YES 126 18 1.3 123/25/66/161 39.7 1 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
80 PALAVESAM 61/M GIDDINESS 66 140/70 INFERIOR WALL 24.8 NO NO VEG NO NO NO NO YES 101 25 1.2 133/31/80/111 34.6 1 NORMAL LV FUNCTION/62%/LVH DISCHARGED
81 THANGAVEL 46/M CHEST PAIN 90 150/100 ANTERIOR WALL 24.8 YES YES NON VEG NO YES NO NO NO 73 20 0.9 136/32/80/120 40.5 4 MILD LV DYSFUNCTION/49% DISCHARGED
82 VELSAMY 55/M CHEST PAIN 86 140/80 INFEROPOSTERIOR WALL 24.9 YES YES NON VEG NO NO NO NO YES 94 24 0.6 97/20/59/89 30.9 1 NORMAL LV FUNCTION/58% DISCHARGED
83 PURUSHOTHAMAN 70/M BREATHLESSNESS 83 100/60 INFERIOR WALL 24.1 YES YES NON VEG NO NO NO NO NO 216 40 1.2 225/41/144/198 37.6 7 MILD LV DYSFUNCTION/45% DISCHARGED
84 KOVILPICHAI 50/M BREATHLESSNESS 98 160/100 ANTEROLATERAL 23.1 YES YES NON VEG NO YES NO NO NO 90 33 1.2 136/26/84/130 36.8 3 MILD LV DYSFUNCTION/46% DISCHARGED
85 SUBRAMANIYAN 84/M CHEST PAIN 60 170/110 INFERIOR WALL 21.9 YES YES NON VEG NO NO YES YES NO 186 53 1.5 130/30/70/154 43.6 5 MODERATE LV DYSFUNCTION/32%LVH DISCHARGED
86 MILTON 38/M CHEST PAIN 110 90/60 EXTENSIVE ANTERIOR WALL 27.1 YES YES NON VEG YES YES NO NO NO 144 58 1.2 164/39/100/130 46.8 9 DEATH
87 BAGAVATHY 55/F CHEST PAIN 94 180/110 ANTERIOR WALL 27.9 NO NO NON VEG YES YES YES YES NO 266 54 1.1 186/36/120/153 35.5 3 MILD LV DYSFUNCTION/49% DISCHARGED
88 KANNAN 63/M GIDDINESS 74 150/110 INFEROPOSTERIOR WALL 22.8 YES YES NON VEG NO YES NO YES NO 126 32 1.3 152/22/110/104 34.9 2 NORMAL LV FUNCTION/58%/LVH DISCHARGED
89 MARIMUTHU 70/M GIDDINESS 56 190/100 INFERIOR WALL 21.8 YES NO NON VEG NO NO YES YES NO 170 56 0.9 135/30/76/96 39.5 4 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
90 SORNAM 68/F CHEST PAIN 94 180/100 ANTERIOR WALL 28.8 NO NO NON VEG YES YES YES YES YES 310 46 1.3 160/34/110/86 40.5 4 MILD LV DYSFUNCTION/49% DISCHARGED
91 PERUMAL 45/M GIDDINESS 64 140/100 INFEROPOSTERIOR WALL 21.4 YES YES NON VEG NO YES NO NO NO 110 41 0.9 140/26/88/130 32.3 1 NORMAL LV FUNCTION/60% DISCHARGED
92 MURUGESAN 46/M CHEST PAIN 106 160/100 ANTERIOR WALL 29.3 YES YES NON VEG YES YES NO NO NO 160 36 0.7 180/38/112/146 37.6 6 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
93 SIVABALAN 70/M GIDDINESS 70 170/100 INFERIOR WALL 21.5 YES YES NON VEG NO NO NO YES NO 106 30 0.9 140/30/88/110 38.7 3 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
94 SAMSUDEEN 37/M BREATHLESSNESS 104 150/100 EXTENSIVE ANTERIOR WALL 26.9 YES YES NON VEG YES NO NO NO YES 116 47 1.2 170/28/120/110 40.6 3 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
95 NALLAKANNU 35/M CHEST PAIN 84 140/90 ANTERIOR WALL 26.6 YES YES NON VEG YES YES NO NO NO 132 32 1.3 130/30/64/180 30.2 2 MILD LV DYSFUNCTION/49% DISCHARGED
96 CHINNATHAMBI 47/M CHEST PAIN 78 160/100 ANTEROSEPTAL 26.1 YES YES NON VEG YES YES NO YES YES 170 36 1.3 182/36/116/150 38.6 3 MILD LV DYSFUNCTION/46% DISCHARGED
97 ESAKKIPANDI 59/M CHEST PAIN 84 110/70 INFERIOR WALL 23.1 YES YES NON VEG NO NO YES NO YES 212 36 1.3 130/30/74/130 29.5 3 MILD LV DYSFUNCTION/49% DISCHARGED
98 PALAVESAMUTHU 75/M GIDDINESS 86 110/80 INFERIOR WALL 27.3 YES YES NON VEG YES YES NO NO NO 156 34 1.2 162/38/90/170 30.1 4 MILD LV DYSFUNCTION/44% DISCHARGED
99 BALASUBBU 53/M CHEST PAIN 68 110/80 INFEROPOSTERIOR WALL 28.6 YES YES NON VEG YES YES YES NO NO 270 36 1.4 178/38/104/180 39.9 3 MILD LV DYSFUNCTION/45% DISCHARGED
100 ESAKKI 60/M CHEST PAIN 78 140/90 ANTERIOR WALL 26.5 YES YES NON VEG YES YES NO NO NO 89 35 1.1 146/36/92/90 40.5 3 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
101 SHANMUGAMAL 65/F CHEST PAIN 76 160/110 ANTERIOR WALL 28.9 NO NO NON VEG YES YES YES NO YES 284 40 1.3 172/30/108/170 39.4 5 MILD LV DYSFUNCTION/46% DISCHARGED
102 SANKAR 70/M GIDDINESS 68 140/90 ANTEROSEPTAL 22.1 YES YES NON VEG NO NO NO NO NO 116 42 0.9 164/30/108/132 29.9 7 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
103 ESAKKIAMMAL 75/F GIDDINESS 64 170/110 INFERIOR RVMI 26.7 NO NO NON VEG YES YES NO YES NO 146 44 1.4 182/34/118/148 40.7 7 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
104 JANAKI 55/F CHEST PAIN 86 170/100 EXTENSIVE ANTERIOR WALL 21.9 NO NO VEG NO NO YES YES NO 250 41 1.4 150/30/92/140 33.8 4 MILD LV DYSFUNCTION/45% DISCHARGED
105 MUTHUSAMY 55/M CHEST PAIN 68 110/60 INFERIOR WALL 28.1 NO YES NON VEG YES YES NO NO YES 152 42 1.3 200/40/136/120 38.9 1 MILD LV DYSFUNCTION/46% DISCHARGED
106 MUTHU 56/M GIDDINESS 74 120/70 INFERIOR/RVMI 28.6 YES YES NON VEG YES YES YES YES YES 252 40 1.2 164/30/108/134 39.7 2 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
107 PETCHIKUTTI 35/M CHEST PAIN 84 140/80 ANTERIOR WALL 26.3 YES YES NON VEG YES NO YES YES YES 272 46 1.3 180/38/108/170 34.5 4 MILD LV DYSFUNCTION/48% DISCHARGED
108 NAINAR 50/M CHEST PAIN 106 80/60 EXTENSIVE ANTERIOR WALL 29.1 YES YES NON VEG YES YES YES NO NO 286 70 1.1 184/26/118/204 46.6 10 DEATH
109 RAMASWAMY 76/M CHEST PAIN 84 110/80 INFEROPOSTERIOR WALL 28.5 YES YES NON VEG YES NO YES NO YES 202 40 1.2 178/40/102/180 40.4 5 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
110 MANONMANI 60/F GIDDINESS 90 120/80 INFEROPOSTERIOR WALL 21.8 NO NO NON VEG NO NO NO NO YES 146 40 1.1 146/30/80/180 30.5 2 MILD LV DYSFUNCTION/46% DISCHARGED
111 ISHA 45/M CHEST PAIN 82 150/100 ANTERIOR WALL 21.6 YES YES NON VEG NO NO NO YES YES 165 32 0.8 126/27/83/80 39.5 3 MILD LV DYSFUNCTION/46%/LVH DISCHARGED
112 ABDUL KADHAR 55/M CHEST PAIN 76 120/70 ANTEROSEPTAL 21.7 YES YES NON VEG NO NO YES NO NO 194 30 1.2 166/26/120/104 38.6 4 MILD LV DYSFUNCTION/49%/LVH DISCHARGED
113 THIRUMALAI 50/F CHEST PAIN 103 160/100 ANTERIOR WALL 29.3 YES YES NON VEG YES YES YES YES NO 132 50 0.7 160/27/103/146 49.5 5 DEATH
114 SAHUL HAMEED 75/M GIDDINESS 60 90/60 INFERIOR 23.9 YES YES NON VEG NO NO NO NO NO 116 39 0.8 174/30/128/84 34.4 9 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
115 PARAMASIVAN 47/M CHEST PAIN 110 100/60 EXTENSIVE ANTERIOR WALL 22.3 YES YES NON VEG NO NO NO NO NO 111 46 0.8 184/30/126/136 43.3 9 SEVERE LV DYSFUNCTION/25%/LV DILATED DISCHARGED
116 GURUSAMY 45/M CHEST PAIN 106 86/60 ANTEROLATERAL 26.2 YES YES NON VEG YES YES NO NO YES 142 30 0.9 154/31/100/116 46.1 10 DEATH
117 CHELLAIAH 60/M GIDDINESS 72 130/80 INFEROPOSTERIOR WALL 21.8 YES YES NON VEG NO NO NO NO NO 130 24 0.8 190/32/132/136 28.4 2 NORMAL LV FUNCTION/58% DISCHARGED
118 ELISHA JACOB 53/F CHEST PAIN 108 96/60 ANTERIOR WALL 27.7 NO NO VEG YES YES YES NO NO 266 42 1.4 182/38/120/122 40.4 8 DEATH
119 PALPANDI 75/M CHEST PAIN 62 180/100 INFEROPOSTERIOR WALL 22.2 YES YES NON VEG NO NO NO YES NO 166 31 0.9 146/32/94/104 30.4 5 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
120 PADMAVATHY 56/F CHEST PAIN 96 160/100 ANTERIOR WALL 28.6 NO NO VEG YES YES YES YES NO 290 56 0.9 208/40/128/199 30.6 5 MILD LV DYSFUNCTION/46%/LVH DISCHARGED
121 RATHINAM 70/M GIDDINESS 66 100/60 INFERIOR WALL 21.7 YES NO NON VEG NO YES NO NO NO 122 38 1.2 146/24/98/118 48.8 9 DEATH
122 GANAPATHY 70/M CHEST PAIN 98 180/100 EXTENSIVE ANTERIOR WALL 21.9 YES YES NON VEG NO NO NO YES NO 146 36 0.9 184/36/126/110 45.4 6 SEVERE LV DYSFUNCTION/24%/LVDILATED DISCHARGED
123 KRISHNASAMY 51/M GIDDINESS 90 160/100 INFEROPOSTERIOR WALL 28.4 NO NO VEG YES YES NO YES NO 121 19 0.7 160/24/110/130 33.1 1 MILD LV DYSFUNCTION/49% DISCHARGED
124 MOOKAN 70/M CHEST PAIN 110 90/60 ANTERIOR WALL 29.8 YES YES NON VEG YES NO YES NO NO 166 38 1.4 166/36/106/120 49.4 12 DEATH
125 CHITHRAKANI 58/M CHEST PAIN 102 90/60 EXTENSIVE ANTERIOR WALL 26.9 YES YES NON VEG YES YES YES NO YES 190 40 0.7 164/30/108/130 45.7 10 DEATH
126 NAGOORMESHA 60/M BREATHLESSNESS 62 130/70 INFEROPOSTERIOR WALL 27.3 NO NO NON VEG YES YES YES NO YES 261 41 1.3 184/38/116/136 34.4 2 MILD LV DYSFUNCTION/44% DISCHARGED
127 PALKANI 64/M GIDDINESS 90 150/90 INFERIOR/RV MI 28.2 NO NO NON VEG YES YES NO NO NO 90 45 0.9 174/38/108/138 36.2 1 NORMAL LV FUNCTION/56% DISCHARGED
128 UDAIYAR 75/M BREATHLESSNESS 90 180/100 ANTERIOR WALL 22.6 NO NO VEG NO NO NO YES NO 74 23 0.9 140/20/96/124 30.7 8 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
129 GANAPATHY 72/M CHEST PAIN 94 140/80 ANTEROSEPTAL 21.8 NO NO VEG NO NO NO NO NO 110 20 0.9 148/34/92/110 37.6 4 MILD LV DYSFUNCTION/48% DISCHARGED
130 ESAKKI 42/M CHEST PAIN 92 150/90 ANTEROSEPTAL 23.3 YES YES NON VEG NO NO NO NO NO 111 40 0.9 146/28/92/130 39.8 3 MILD LV DYSFUNCTION/48% DISCHARGED
131 GNAKKAN 73/M CHEST PAIN 90 100/90 INFERIOR WALL 22.9 YES YES NON VEG NO NO NO YES NO 160 19 1.1 184/36/106/136 39.1 5 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
132 VELAPPAN 72/M GIDDINESS 98 160/100 EXTENSIVE ANTERIOR WALL 24.2 YES YES NON VEG NO NO NO YES NO 116 33 0.9 196/38/140/138 39.5 6 MILD LV DYSFUNCTION/44% DISCHARGED
133 PERUMAL 45/M CHEST PAIN 84 150/90 ANTERIOR WALL 29.4 YES YES NON VEG YES NO YES NO NO 272 38 1.5 190/38/118/170 38.7 3 MILD LV DYSFUNCTION/48% DISCHARGED
134 INNARIMUTHU 64/M CHEST PAIN 84 110/70 INFERIOR WALL 27.7 YES YES NON VEG YES YES NO NO YES 121 36 1.2 190/40/114/180 35.6 1 MILD LV DYSFUNCTION/48% DISCHARGED
135 PANDI 45/M CHEST PAIN 90 160/90 ANTERIOR WALL 20.6 YES YES NON VEG NO NO YES YES YES 321 42 1.2 180/28/120/160 39.6 4 MILD LV DYSFUNCTION/50% DISCHARGED
136 MUPPIDATHY 65/M CHEST PAIN 94 180/110 INFERIOR WALL 23.6 YES YES NON VEG NO NO NO NO NO 116 46 1 178/38/110/146 30.6 4 MILD LV DYSFUNCTION/48% DISCHARGED
137 ABDUL KADAR 53/M CHEST PAIN 76 140/90 ANTEROSEPTAL 28.4 YES YES NON VEG YES YES NO NO NO 146 34 0.9 164/42/87/188 40.7 3 MILD LV DYSFUNCTION/48% DISCHARGED
138 PETCHIAPPAN 45/M CHEST PAIN 96 170/90 ANTEROSEPTAL 23.6 YES YES NON VEG NO NO NO NO NO 116 42 1.1 174/42/104/140 33.5 4 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
139 KOILAMMAL 55/F CHEST PAIN 90 160/90 EXTENSIVE ANTERIOR WALL 27.4 NO NO NON VEG YES YES YES NO NO 164 36 1.2 190/38/120/160 34.6 4 MILD LV DYSFUNCTION/40%/LVH DISCHARGED
140 SUMITHA 50/F CHEST PAIN 64 110/60 INFERIOR WALL 28.4 NO NO NON VEG YES YES YES NO NO 269 47 1.1 180/46/110/120 29.6 2 MILD LV DYSFUNCTION/48% DISCHARGED
141 ARUMAIRAJ 69/M CHEST PAIN 106 160/100 ANTERIOR WALL 28.6 YES NO NON VEG YES YES NO YES NO 116 42 1.6 188/38/118/160 40.2 8 MODERATE LV DYSFUNCTION/32%/LVH DISCHARGED
142 RAJU 75/M GIDDINESS 94 180/100 ANTERIOR WALL 24.8 NO YES NON VEG NO NO YES YES NO 188 46 0.9 144/36/80/140 34.5 7 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
143 SARASWATHI 72/F BREATHLESSNESS 68 180/100 INFERIOR WALL 29.4 NO NO VEG YES YES YES YES NO 246 46 1.2 160/28/102/150 35.7 6 MILD LV DYSFUNCTION/46%/LVH DISCHARGED
144 AYANUSAMY 54/M CHEST PAIN 96 150/90 ANTEROSEPTAL 23.6 YES YES NON VEG NO NO NO NO NO 106 29 0.7 130/28/82/100 35.9 1 MILD LV DYSFUNCTION/46% DISCHARGED
145 SUDALAI 40/M CHEST PAIN 104 110/50 EXTENSIVE ANTERIOR WALL 23.9 YES NO NON VEG NO NO NO NO NO 76 31 1.1 198/38/130/150 38.7 6 MILD LV DYSFUNCTION / 40%/LV DILATED DISCHARGED
146 SEEMAN 50/M CHEST PAIN 84 140/90 LATERAL WALL 24.6 YES YES NON VEG NO NO NO NO NO 102 16 0.7 164/32/110/110 36.8 1 NORMAL/54% DISCHARGED
147 VEERABAGU 70/M CHEST PAIN 104 100/60 ANTERIOR WALL 22.8 NO NO VEG NO NO YES NO NO 174 30 0.9 130/18/92/100 41.1 12 MODERATE LV DYSFUNCTION/36%/LVH DISCHARGED
148 BASKARAN 68/M CHEST PAIN 90 160/100 INFERIOR WALL 29.6 YES NO NON VEG YES YES NO NO NO 102 37 0.9 186/34/123/146 34.5 4 MILD LV DYSFUNCTION/47%/LVH DISCHARGED
149 SAROJA 67/F GIDDINESS 68 140/90 INFERIOR WALL 27.3 NO NO VEG YES YES YES NO NO 269 41 1.1 240/46/154/190 37.4 4 MILD LV DYSFUNCTION/42% DISCHARGED
150 KAJAMYDEEN 47/M CHEST PAIN 60 130/80 INFERIOR WALL 22.1 YES NO NON VEG NO NO YES NO YES 184 48 1.2 180/40/112/140 37.9 1 NORMAL/58.1% DISCHARGED
151 PAVANASAM 55/M CHEST PAIN 64 130/80 POSTERIOR WALL 22.7 YES YES NON VEG NO NO NO NO NO 122 21 0.6 148/30/98/108 36.8 1 NORMAL/56% DISCHARGED
152 MUPPIDATHY 55/F CHEST PAIN 64 150/80 ANTEROSEPTAL 22.1 NO NO VEG NO NO YES YES YES 136 41 1.1 138/38/80/106 29.6 4 MILD LV DYSFUNCTION/46%/LVH DISCHARGED
153 ANNAMAL 60/F CHEST PAIN 64 140/80 INFEROPOSTERIOR WALL 27.6 NO NO NON VEG YES YES NO NO NO 116 31 0.8 144/28/96/102 36.9 3 MILD LV DYSFUNCTION/48% DISCHARGED
154 RAMASAMY 45/M CHEST PAIN 92 160/90 LATERAL WALL 22.8 YES YES NON VEG NO NO NO YES YES 141 34 0.7 134/23/90/104 39.9 4 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
155 KEERTHIRAM 49/M CHEST PAIN 89 140/80 ANTEROSEPTAL 21.9 NO NO VEG NO NO YES NO NO 160 19 0.7 174/29/110/190 39.7 3 MILD LV DYSFUNCTION/44.1% DISCHARGED
156 RAMASAMY 40/M CHEST PAIN 79 160/100 ANTERIOR WALL 23.6 YES YES NON VEG NO NO NO NO YES 84 27 0.8 174/34/112/140 36.7 3 MILD LV DYSFUNCTION/47% DISCHARGED
157 SARASWATHY 78/F GIDDINESS 58 140/80 INFERIOR WALL 20.4 NO NO VEG NO NO YES NO NO 166 39 1.3 176/32/118/134 34.4 6 MILD LV DYSFUNCTION/40% DISCHARGED
158 GANESAN 40/M CHEST PAIN 104 160/90 ANTERIOR WALL 24.7 YES YES NON VEG NO NO NO NO YES 140 33 0.9 180/26/120/174 32.2 3 MILD LV DYSFUNCTION/48% DISCHARGED
159 PALAPPAN 67/M CHEST PAIN 90 130/80 ANTERIOR WALL 27.8 NO NO NON VEG YES YES YES NO NO 164 29 1.2 184/30/130/120 34.9 6 MILD LV DYSFUNCTION/43%/LVH DISCHARGED
160 SAMUEL 50/M CHEST PAIN 106 170/90 ANTEROSEPTAL 20.8 YES YES NON VEG NO NO NO NO NO 138 25 0.7 174/38/108/140 37.6 3 MILD LV DYSFUNCTION/45% DISCHARGED
161 VELLAIMAL 70/F GIDDINESS 68 140/90 LATERAL WALL 28.9 NO NO NON VEG YES YES YES NO NO 262 40 1.6 211/36/143/162 42.8 6 MODERATE LV DYSFUNCTION/32% DISCHARGED
162 KALIMUTHU 74/M GIDDINESS 66 140/90 INFERIOR WALL 22.1 NO YES NON VEG NO NO NO NO NO 96 41 1.2 162/48/86/136 38.7 2 MILD LV DYSFUNCTION/42% DISCHARGED
163 KARUPPIAH 70/M CHEST PAIN 75 160/90 INFEROPOSTERIOR WALL 21.5 YES YES NON VEG NO NO NO NO NO 113 38 1.4 170/40/102/138 38.4 3 MILD LV DYSFUNCTION/47% DISCHARGED
164 SUDALAI 72/M GIDDINESS 56 130/80 INFERIOR WALL 21.8 YES YES NON VEG NO NO NO NO NO 93 33 0.6 138/24/94/98 34.8 2 MILD LV DYSFUNCTION/47% DISCHARGED
165 VEMBU 64/M GIDDINESS 66 170/90 INFERIOR WALL 28.5 NO NO NON VEG YES YES NO YES NO 109 36 1.2 174/34/114/130 29.8 2 NORMAL/54%/LVH DISCHARGED
166 RAMAKRISHNAN 44/M CHEST PAIN 90 160/100 LATERAL WALL 27.4 YES YES NON VEG YES YES NO NO NO 113 44 0.9 138/18/100/102 37.7 3 MILD LV DYSFUNCTION/48% DISCHARGED
167 ASANFATH 65/F CHEST PAIN 82 140/90 ANTEROSEPTAL 28.4 NO NO NON VEG YES YES NO YES NO 96 30 1.2 166/32/110/120 39.6 6 MILD LV DYSFUNCTION/41%/LVH DISCHARGED
168 PONNAMBALAM 62/M CHEST PAIN 94 180/100 ANTERIOR WALL 23.9 NO YES NON VEG NO NO NO YES YES 83 18 0.9 140/28/90/110 37.6 2 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
169 MOHAMMAD 74/M GIDDINESS 66 180/90 INFEROPOSTERIOR WALL 20.8 NO NO NON VEG NO NO YES YES NO 180 41 1.4 182/34/120/140 39.7 5 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
170 KASIMANI 41/M CHEST PAIN 104 140/90 ANTERIOR WALL 22.8 YES YES NON VEG NO NO NO NO YES 90 19 0.7 138/28/90/100 39.6 5 MILD LV DYSFUNCTION/42% DISCHARGED
171 VASANTHA 49/F CHEST PAIN 58 150/90 INFERIOR WALL 27.9 NO NO VEG YES NO YES NO NO 188 40 1.1 190/40/124/128 35.9 1 MILD LV DYSFUNCTION/46% DISCHARGED
172 MOHD ALI 64/M CHEST PAIN 106 150/90 ANTEROSEPTAL 24.4 NO NO NON VEG NO NO YES YES NO 176 39 1.2 180/32/120/140 37.5 7 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
173 CHINNATHAI 60/F CHEST PAIN 92 160/100 ANTEROSEPTAL 30.4 NO NO VEG YES YES NO YES NO 130 39 1.3 162/30/110/110 36.7 4 MILD LV DYSFUNCTION/45%/LVH DISCHARGED
174 MAYANDI 55/M CHEST PAIN 62 140/80 INFEROPOSTERIOR WALL 23.9 YES YES NON VEG NO NO NO NO YES 84 19 0.7 132/34/80/88 40.3 1 NORMAL/58% DISCHARGED
175 PANDARAM 45/M CHEST PAIN 78 130/90 LATERAL WALL 22.8 YES YES NON VEG NO NO NO NO NO 122 30 1.2 138/22/96/98 30.8 2 NORMAL/56% DISCHARGED
176 MOOKAN 55/M GIDDINESS 58 160/100 INFERIOR WALL 24.4 YES YES NON VEG NO NO NO NO NO 101 29 0.8 152/34/96/110 38.6 1 MILD LV DYSFUNCTION/48% DISCHARGED
177 MARIMUTHU 55/M CHEST PAIN 86 170/100 ANTERIOR WALL 21.4 YES YES NON VEG NO NO NO NO YES 102 30 0.7 184/38/120/130 39.1 3 MILD LV DYSFUNCTION/44% DISCHARGED
178 PAPPA 67/F CHEST PAIN 82 110/70 INFERIOR WALL 18.3 NO NO NON VEG NO NO YES NO YES 278 36 1.3 175/35/110/150 29.6 4 MILD LV DYSFUNCTION/46% DISCHARGED
179 SUNDARAJ 35/M CHEST PAIN 82 150/100 ANTEROSEPTAL 29.6 YES YES NON VEG YES YES NO NO YES 272 40 1.2 180/36/110/170 43.4 2 MILD LV DYSFUNCTION/48% DISCHARGED
180 RAMAIAH 63/M CHEST PAIN 82 140/80 ANTEROSEPTAL 27.2 YES YES NON VEG YES NO NO YES NO 190 40 1.3 190/38/115/185 40.6 3 MILD LV DYSFUNCTION/48% DISCHARGED
181 ARPUTHAM 57/F CHEST PAIN 86 120/80 INFERIOR WALL 24.3 NO NO VEG NO NO NO NO NO 128 36 1.3 197/40/124/165 38.6 2 MILD LV DYSFUNCTION/49% DISCHARGED
182 SETHU 50/M CHEST PAIN 98 120/60 INFERIOR WALL 28.4 YES YES NON VEG YES NO YES NO YES 220 38 1.2 192/38/119/175 30.6 2 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
183 SUDALAIMANI 52/M CHEST PAIN 92 160/110 EXTENSIVE ANTERIOR WALL 27.9 YES YES NON VEG YES YES NO NO NO 112 28 0.7 186/42/98/152 39.5 2 MODERATE LV DYSFUNCTION/33% DISCHARGED
184 KRISHNAN 75/M BREATHLESSNESS 92 180/100 ANTERIOR WALL 27.8 YES NO NON VEG YES YES NO NO NO 123 39 1 186/38/114/170 36 5 MILD LV DYSFUNCTION/45% DISCHARGED
185 BASKARAN 74/M CHEST PAIN 84 170/110 ANTERIOR WALL 28.9 NO NO VEG YES YES NO NO NO 128 38 1.2 186/38/114/170 40.5 4 MILD LV DYSFUNCTION/48% DISCHARGED
186 BEEVI 55/F CHEST PAIN 68 160/100 INFERIOR WALL 26.7 NO NO NON VEG YES YES NO YES YES 118 30 1.2 130/22/86/110 33.1 1 NORMAL/54%/LVH DISCHARGED
187 SUDALAIMADAN 65/M CHEST PAIN 90 170/100 ANTERIOR WALL 24.2 NO NO NON VEG NO NO NO YES NO 130 46 0.9 164/20/106/190 39.6 5 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
188 CHELLAIAH 55/M CHEST PAIN 58 180/100 INFEROPOSTERIOR WALL 26.9 YES YES NON VEG YES YES NO YES NO 114 41 1.2 174/40/98/186 30.6 1 NORMAL/56%/LVH DISCHARGED
189 GOMATHY 70/F CHEST PAIN 86 150/90 ANTEROSEPTAL 29.8 NO NO VEG YES YES NO YES YES 116 39 0.9 174/38/100/180 39.5 6 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
190 MUPPIDATHY 60/F CHEST PAIN 64 180/100 INFERIOR WALL 27.6 NO NO NON VEG YES YES NO YES NO 78 30 1 173/33/110/150 33.5 1 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
191 LAKSHMI 56/F CHEST PAIN 76 140/80 ANTEROSEPTAL 28.4 NO NO VEG YES YES YES NO NO 166 39 1.3 133/30/67/180 32.1 3 MILD LV DYSFUNCTION/43% DISCHARGED
192 SUBBIAH 65/M CHEST PAIN 90 160/80 ANTERIOR WALL 27.9 NO NO VEG YES YES YES NO NO 133 33 0.7 246/42/168/180 39.2 4 MILD LV DYSFUNCTION/48% DISCHARGED
193 MARIAMMAL 65/F CHEST PAIN 56 160/90 INFERIOR WALL 20.8 NO NO VEG NO NO NO YES NO 112 40 1.6 186/36/120/150 35.8 3 MILD LV DYSFUNCTION/44%/LVH DISCHARGED
194 PARVATHY 75/F GIDDINESS 64 170/100 INFERIOR WALL 24.8 NO NO VEG NO NO YES YES NO 180 41 1.2 184/34/118/160 39.6 6 MILD LV DYSFUNCTION/48%/LVH DISCHARGED
195 RAMAPANDIAN 75/M BREATHLESSNESS 104 180/100 ANTERIOR WALL 22.9 YES NO NON VEG NO NO NO YES NO 134 38 1.2 212/30/150/160 42.2 10 MODERATE LV DYSFUNCTION/34%/LVH DISCHARGED
196 ARULDOSS 58/M CHEST PAIN 68 140/90 INFEROLATERAL WALL 23.7 YES YES NON VEG NO NO YES NO NO 190 16 0.7 155/37/91/135 39.6 3 MILD LV DYSFUNCTION/46% DISCHARGED
197 SUBBAMAL 65/F CHEST PAIN 66 150/80 INFERIOR WALL 28.4 NO NO VEG YES YES YES NO NO 217 41 1.1 171/33/120/137 34.4 6 MILD LV DYSFUNCTION/45% DISCHARGED
198 SUDALAIMUTHU 57/M CHEST PAIN 98 170/100 EXTENSIVE ANTERIOR WALL 23.5 YES YES NON VEG NO NO YES YES YES 184 38 1.4 194/42/126/130 38.6 4 MILD LV DYSFUNCTION/43%/LVH DISCHARGED
199 THANGAVEL 73/M GIDDINESS 64 160/100 LATERAL WALL 20.6 YES NO NON VEG NO NO YES YES NO 184 38 1.2 214/38/140/184 35.5 5 MILD LV DYSFUNCTION/42%/LVH DISCHARGED
200 SELVAMUTHU 43/M CHEST PAIN 70 140/80 INFERIOR/RV MI 21.7 YES YES NON VEG NO NO NO NO NO 89 26 0.8 166/36/96/170 30.3 2 NORMAL/58% DISCHARGED
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           ANNEXURE-3 
KEY TO MASTER CHART 
Sex: 
M- Male, F-Female 
Presenting Complaints: 
        Chest Pain, Giddiness, Palpitation, Breathlessness 
MI Type:  
    Anterior Wall, Anteroseptal Wall, Anterolateral Wall, Extensive Anterior Wall,  
Inferior Wall, Inferoposterior Wall, Lateral Wall, Inferior/Right Ventricular Wall 
BMI: 
<18.5- Underweight, 18.5 to 24.9- Normal weight, 25 to 29.9-Overweight, 
30 and above – Obese 
Food Habits: 
         Vegetarian, Non-Vegetarian 
RiskFactors:(Smoking to Family History of CAD) 
                   YES, NO 
Echo Study: 
  Normal Left Ventricular function,Mild Left Ventricular Dysfunction, Moderate 
Left Ventricular Dysfunction, Severe Left Ventricular Dysfunction 
Outcome: 
Discharge, Death. 
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ANNEXURE-4 
ABBREVIATIONS 
 BP- Blood Pressure 
CAD- Coronary Artery Disease 
CHD-Coronary Heart Disease 
CVD-Cardio Vascular Disease 
ECG- Electrocardiogram 
LMCA-Left Main Coronary Artery 
LAD-Left Anterior Descending Artery 
LCX-Left Circumflex Artery 
RCA-Right Coronary Artery 
LV -  Left Ventricle 
MI- Myocardial Infarction 
TIMI-Thrombolysis in Myocardial Infarction  
STEMI- ST Elevation Myocardial Infarction 
CPK-MB – CreatininePhospho Kinase - MB Isoenzyme 
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DHA-Docosa Hexaenoic Acid 
EPA- Eicosa Pentaenoic Acid 
ALA-Alpha Linoleic Acid 
LA- Linoleic Acid  
HDL- High Density Lipoprotein 
LDL-Low Density Lipoprotein 
VLDL- Very Low Density Lipoprotein 
TG-Triglycerides 
SFA- Saturated Fatty Acids 
MUFA- MonoUnsaturated Fatty Acids 
PUFA-Poly Unsaturated Fatty Acids 
TFA- Trans Fatty Acids 
WHO-World Health Organisation 
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